<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">4vYzpzBfgzwd6NNzSy4GQCN</article-id>
      <article-id pub-id-type="other">00018</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000900018</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09300318</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000900018</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Correla&#231;&#227;o Anatomo-Cl&#237;nica</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Caso 4/2009: homem de 55 anos com cardiomiopatia da doen&#231;a de Chagas que evoluiu com dispn&#233;ia progressiva, dor tor&#225;cica e infiltrado intersticial pulmonar</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Bolonhez</surname>
            <given-names>Angela Cristina Matera</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Silva</surname>
            <given-names>Murilo Capreti da</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chate</surname>
            <given-names>Rodrigo Caruso</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gutierrez</surname>
            <given-names>Paulo Sampaio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Instituto do Cora&#231;&#227;o </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>09</month>
        <year>2009</year>
      </pub-date>
      <volume>93</volume>
      <issue>3</issue>
      <fpage>316</fpage>
      <lpage>322</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <pub-date publication-format="electronic" date-type="pub">
        <day>22</day>
        <month>10</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>CORRELA&#199;&#195;O ANATOMO-CL&#205;NICA</bold>
    </p>
    <p>
      <bold>Caso 4/2009 - homem de 55 anos com cardiomiopatia da doen&#231;a de Chagas que evoluiu com dispn&#233;ia progressiva, dor tor&#225;cica e infiltrado intersticial pulmonar</bold>
    </p>
    <p>
      <bold>Angela Cristina Matera Bolonhez; Murilo Capreti da Silva; Rodrigo Caruso Chate; Paulo Sampaio Gutierrez</bold>
    </p>
    <p>Instituto do Cora&#231;&#227;o (InCor) HC-FMUSP, S&#227;o Paulo</p>
    <p><bold>Palavras Chave:</bold> Doen&#231;a de chagas, dispn&#233;ia, bloqueio de ramo, disfun&#231;&#227;o ventricular.</p>
    <p>Homem de 55 anos de idade, pedreiro aposentado, natural de Itapetim (PE) procurou atendimento m&#233;dico em raz&#227;o de falta de ar (4/11/2005).  </p>
    <p>H&#225; tr&#234;s anos, passou a apresentar dispneia de intensidade progressiva, a princ&#237;pio desencadeada por grandes esfor&#231;os. H&#225; um ano, a falta de ar passou a aparecer com esfor&#231;os moderados, associada a palpita&#231;&#245;es taquic&#225;rdicas. Procurou atendimento m&#233;dico em Unidade B&#225;sica de Sa&#250;de, recebeu prescri&#231;&#227;o de medicamentos dos quais n&#227;o se lembra. Melhorou depois do uso dos medicamentos. Recebeu informa&#231;&#227;o pr&#233;via de ser portador de doen&#231;a de Chagas.</p>
    <p>O paciente vinha em uso de carvedilol 3,125 mg duas vezes ao dia, de digoxina 0,25 mg, espironolactona 25 mg, &#225;cido acetilsalic&#237;lico 100 mg, hidroclorotiazida 25 mg associada a amilorida 2,5 mg &#189; cp di&#225;rios. </p>
    <p>O exame f&#237;sico revelou peso de 74,8 kg, altura de 1,64 m, &#237;ndice de massa corp&#243;rea 27,8 kg/m<sup>2</sup>, pulso de 78 batimentos por minuto, press&#227;o arterial de 110/80 mmHg. O exame dos pulm&#245;es foi normal. O exame do cora&#231;&#227;o revelou bulhas r&#237;tmicas, bulhas normais, sem bulhas acess&#243;rias, sem estalidos ou sopros card&#237;acos. O exame do abdome foi normal. N&#227;o havia edema de membros. </p>
    <p>O eletrocardiograma (1/11/2005) revelou ritmo sinusal e ondas R de baixa amplitude em deriva&#231;&#245;es de extremidades e em deriva&#231;&#245;es precordiais, al&#233;m de dist&#250;rbio da condu&#231;&#227;o intraventricular do est&#237;mulo e sobrecarga ventricular e atrial esquerdas (<xref ref-type="fig" rid="fig01">Figura 1</xref>).</p>
    <fig id="fig01">
      <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf01.jpg"/></fig>
    <p>A radiografia do t&#243;rax revelou cardiomegalia +++/4. </p>
    <p>Foi feito o diagn&#243;stico de insufici&#234;ncia card&#237;aca por cardiomiopatia da doen&#231;a de Chagas. </p>
    <p>Foi feito o ajuste de medica&#231;&#227;o com suspens&#227;o do &#225;cido acetilsalic&#237;lico e a associa&#231;&#227;o hidroclorotiazida/amilorida, aumento da dose de carvedilol para 6,25 mg 2x/dia, e acrescentado enalapril 10 mg 2x/dia.</p>
    <p>O teste para detec&#231;&#227;o de anticorpos anti <italic>Trypanosoma cruzi</italic> (3/11/2005) demonstrou soro reagente.</p>
    <p>A radiocardiografia ("gated blood pool") (14/6/2006) com hem&#225;cias marcadas com <sup>99m</sup>Tecn&#233;cio revelou ritmo de clareamento ventricular do tra&#231;ador alterado bilateralmente e tronco de art&#233;ria pulmonar abaulado. O tempo m&#233;dio de tr&#226;nsito pulmonar foi superior a 20 segundos. O &#225;trio e o ventr&#237;culo direitos encontravam-se aumentados de volume. Havia hipocinesia difusa acentuada do ventr&#237;culo direito. O ventr&#237;culo esquerdo estava aumentado em grau acentuado e havia hipocinesia difusa acentuada e discinesia da regi&#227;o &#237;nfero-apical do ventr&#237;culo esquerdo. A regi&#227;o &#237;nfero-apical do ventr&#237;culo esquerdo movimentava-se em oposi&#231;&#227;o de fase em rela&#231;&#227;o &#224;s demais paredes. A fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo foi estimada em 13% e do ventr&#237;culo direito 24%.</p>
    <p>A avalia&#231;&#227;o laboratorial (13/07/2006) revelou hemoglobina 18,1 g/dl, hemat&#243;crito 54%, VCM 100 fl, CHCM 34 g/dl, 5400000 eritr&#243;citos por mm<sup>3</sup>, 6900 leuc&#243;citos por mm<sup>3</sup> (neutr&#243;filos 72%, eosin&#243;filos 2%, linf&#243;citos 18%, mon&#243;citos 8%), s&#243;dio 137 mEq/l, pot&#225;ssio 5,1 mEq/l, ureia 82 mg/dL, creatinina 1,1 mg/dl, aspartato aminotransferase 36 U/l alanina aminotransferase 56 U/l, &#225;cido &#250;rico 7,3 mg/dl, albumina 3,7 g/dl, bilirrubina total 1,36 mg/dl (direta 0,68 mg/dl, indireta 0,68 mg/dl), tempo de protrombina 19,3 seg (INR 1,45), prote&#237;n&#250;ria de 24 h 0,14g (normal at&#233; 0,15). O exame parasitol&#243;gico de fezes (Hoffman, Rugai) foi negativo, ant&#237;geno carcinoembrion&#225;rio 2,8 ng/ml (refer&#234;ncia at&#233; 5,0 ng/ml).</p>
    <p>Foi submetido a cateterismo card&#237;aco (3/8/2006) o qual revelou hipertens&#227;o pulmonar moderada (<xref ref-type="table" rid="tab01">Tabela 1</xref>) e n&#227;o demonstrou les&#245;es obstrutivas em art&#233;rias coron&#225;rias. </p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gt01.jpg"/></table-wrap>
    <p>A cintilografia pulmonar ventila&#231;&#227;o perfus&#227;o (12/9/2006) foi considerada como de baixa probabilidade de embolia pulmonar. </p>
    <p>Em 6/10/2006, queixou-se de cansa&#231;o aos esfor&#231;os e edema de membros inferiores. Foi aumentada a dose dos diur&#233;ticos, para furosemida 80 mg di&#225;rios, al&#233;m da medica&#231;&#227;o que j&#225; vinha recebendo.</p>
    <p>Em 3/11/2006, a ureia foi 81 mg/dl, creatinina foi 1,55 mg/dl e o pot&#225;ssio s&#233;rico 4,9 mEq/l.</p>
    <p>Em um dos retornos ambulatoriais (4/12/2006) queixou-se de falta de ar, epis&#243;dios de tontura e h&#225; 15 dias pr&#233;-s&#237;ncope. Queixou-se tamb&#233;m de incha&#231;o nas pernas e no abdome. Vinha em uso de hidralazina 25 mg 2x/dia, furosemida 40 mg 2x/dia, al&#233;m da espironolactona, carvedilol, enalapril e digoxina. Foi orientado para ajuste de dieta, atividade e medica&#231;&#227;o: a dose de diur&#233;ticos foi reduzida. </p>
    <p>O ecocardiograma (3/1/2007) revelou aorta 32 mm, &#225;trio esquerdo 52 mm, ventr&#237;culo direito 30 mm, septo interventricular 8 mm, parede posterior de ventr&#237;culo esquerdo 8 mm, di&#226;metro diast&#243;lico do ventr&#237;culo esquerdo 76 mm, di&#226;metro sist&#243;lico do ventr&#237;culo esquerdo 66 mm, fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo (Teicholz) 27%. O estudo com Doppler revelou padr&#245;es de fluxo compat&#237;veis com padr&#227;o restritivo, com revers&#227;o ap&#243;s manobra de Valsalva. As valvas card&#237;acas foram consideradas normais. A press&#227;o sist&#243;lica na art&#233;ria pulmonar foi estimada em 55 mmHg. </p>
    <p>Depois do ajuste da medica&#231;&#227;o em dezembro, houve melhora dos sintomas (12/1/2007).</p>
    <p>A avalia&#231;&#227;o laboratorial na evolu&#231;&#227;o revelou glicemia de jejum 106 mg/dl (18/9/2007), pept&#237;deo natriur&#233;tico tipo B 1021 pg/ml (refer&#234;ncia: &lt;100 pg/ml), colesterol 220 mg/dl, HDL-colesterol 39 mg/dl, LDL-colesterol 157 mg/dl, TSH 2,87 mUI/ml, T<sub>4</sub> livre1,7 ng/dl, glicemia 106 mg/dl e a hemoglobina glicada 6,1%, CA 19,9 2,6 U/ml (refer&#234;ncia at&#233; 37 U/ml) (29/10/2007).</p>
    <p>A ultrassonografia de abdome (12/5/2008) revelou aorta ateromatosa e imagens nodulares hiperecog&#234;nicas hep&#225;ticas que foram consideradas compat&#237;veis com hemangiomas. </p>
    <p>Em 3/6/2008, o paciente apresentou tosse com expectora&#231;&#227;o amarelada, al&#233;m da dispneia. Procurou atendimento em Unidade B&#225;sica de Sa&#250;de e medicado com levofloxacina 500 mg 1x/dia. Houve melhora cl&#237;nica. </p>
    <p>Na evolu&#231;&#227;o procurou atendimento m&#233;dico (3/7/2008) em raz&#227;o de dor precordial persistente por 2 dias, que piorava &#224; inspira&#231;&#227;o profunda ou com a tosse, que se irradiava para o dorso, al&#233;m de tosse com expectora&#231;&#227;o sanguinolenta. </p>
    <p>Vinha em uso de carvedilol 50 mg, enalapril 40 mg, digoxina 0,125 mg, furosemida 40 mg, hidroclorotiazida 25 mg, espironolactona 25 mg, e omeprazol diariamente. </p>
    <p>O exame f&#237;sico revelou pulso de 80 batimentos por minuto, press&#227;o arterial de 80/40 mmHg. No restante do exame f&#237;sico n&#227;o havia registro de dados diagn&#243;sticos. </p>
    <p>O eletrocardiograma em 3/7/2008 n&#227;o demonstrou altera&#231;&#227;o significativa em rela&#231;&#227;o ao electrocardiograma anterior. </p>
    <p>A radiografia do t&#243;rax (3/7/2008) revelou imagem sugestiva de infiltrado reticuloalveolar difuso nos pulm&#245;es. A tomografia de t&#243;rax (3/7/2008) revelou estruturas vasculares mediastinais de calibre normal e contornos regulares, cardiomegalia, linfonodos mediastinais menores que 10 mm, micron&#243;dulos calcificados esparsos por ambos os pulm&#245;es, n&#243;dulo n&#227;o calcificado, de bordas espiculadas medindo 1,6 x 1,4cm no segmento basal medial do LID, micron&#243;dulos de distribui&#231;&#227;o centrolobular difusos por ambos os pulm&#245;es e espessamento de septos interlobulares &#224; direita, Opacidade com atenua&#231;&#227;o em vidro fosco predominando nas por&#231;&#245;es m&#233;dias e base do pulm&#227;o direito, consolida&#231;&#227;o na base do pulm&#227;o direito. </p>
    <p>Foram feitas as hip&#243;teses diagn&#243;sticas de linfangite, estase ou sarcoidose. </p>
    <p>A cultura de escarro para micobact&#233;rias e a pesquisa de bacilos &#225;lcool-&#225;cido resistentes (4/7/2009) foram negativas. </p>
    <p>Foi medicado com claritromicina 500 mg via endovenosa a cada 12 horas, ceftriaxona 1g via endovenosa a cada 12 horas, al&#233;m da medica&#231;&#227;o cardiovascular que fazia uso. Foi associada a administra&#231;&#227;o de dobutamina.</p>
    <p>Em 7/7/2008, apresentou quadro descrito como edema agudo de pulm&#227;o, que melhorou com o uso de diur&#233;ticos, ventila&#231;&#227;o n&#227;o invasiva e vasodilatadores.</p>
    <p>No dia seguinte 8/7/2008 sofreu parada card&#237;aca em atividade el&#233;trica sem pulso, n&#227;o revertida com manobras de reanima&#231;&#227;o. </p>
    <p>
      <bold>Coment&#225;rios &#150; Radiologista de t&#243;rax do InCor </bold>
    </p>
    <p>Na tomografia de t&#243;rax realizada sem contraste iodado intravenoso, identificava-se n&#243;dulo pulmonar n&#227;o calcificado de contornos lobulados no lobo inferior direito, cujo aspecto tomogr&#225;fico favorecia a possibilidade de neoplasia prim&#225;ria (<xref ref-type="fig" rid="fig02">Figura 2</xref>). No pulm&#227;o direito, associava-se espessamento dos interst&#237;cios peribroncovascular e septal, por vezes com aspecto liso e em algumas regi&#245;es com padr&#227;o micronodular, levantando a possibilidade de linfangite carcinomatosa (<xref ref-type="fig" rid="fig02">Figuras 2 a 4</xref>). Destacavam-se ainda m&#250;ltiplos pequenos n&#243;dulos n&#227;o calcificados disseminados por todos os campos pulmonares, que, neste contexto cl&#237;nico, s&#227;o compat&#237;veis com les&#245;es secund&#225;rias (<xref ref-type="fig" rid="fig02">Figuras 2 a 4</xref>). Os cortes tomogr&#225;ficos revelavam ainda focos de consolida&#231;&#227;o pulmonar com base pleural esparsos bilateralmente, circundados por opacidades em vidro fosco, predominando nos segmentos basais do lobo inferior direito (<xref ref-type="fig" rid="fig05">Figura 5</xref>), consistentes com &#225;reas de infarto e hemorragia pulmonar no contexto cl&#237;nico de tromboembolismo agudo. <bold>(Dr. Rodrigo Caruso Chate)</bold></p>
    <fig id="fig02">
      <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf02.jpg"/></fig>
    <p>
      <graphic xlink:href="1678-4170-abc-93-03-0316-00018-e01.jpg"/></p>
    <p>
      <graphic xlink:href="1678-4170-abc-93-03-0316-00018-e02.jpg"/></p>
    <fig id="fig05">
      <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf03.jpg"/></fig>
    <p>
      <bold>Aspectos cl&#237;nicos</bold>
    </p>
    <p>Trata-se de um paciente do sexo masculino, 55 anos de idade, que em novembro de 2005 procurou atendimento por dispneia com piora progressiva havia 3 anos, associada a palpita&#231;&#245;es taquic&#225;rdicas, com sorologia positiva para doen&#231;a de Chagas. O exame f&#237;sico foi normal, o eletrocardiograma (ECG) mostrou bloqueio de ramo esquerdo e ondas R de baixa amplitude, e a radiografia de t&#243;rax evidenciou aumento de &#225;rea card&#237;aca (cardiomegalia 3+/4+), compat&#237;vel com insufici&#234;ncia card&#237;aca de prov&#225;vel etiologia por doen&#231;a de Chagas, na sua forma de miocardiopatia cr&#244;nica dilatada. Fazia uso de baixas doses de carvedilol al&#233;m de digoxina, &#225;cido acetilsalic&#237;lico, espironolactona, hidroclorotiazida e amilorida. Foram ajustadas as medica&#231;&#245;es com introdu&#231;&#227;o de inibidor da enzima conversora da angiotensina (enalapril) e iniciado seguimento.</p>
    <p>Podemos fazer algumas considera&#231;&#245;es a respeito da etiologia da insufici&#234;ncia card&#237;aca. A doen&#231;a de Chagas na sua forma cr&#244;nica caracteriza-se pela diversidade. H&#225; pacientes assintom&#225;ticos na forma indeterminada, os assintom&#225;ticos com altera&#231;&#245;es eletrocardiogr&#225;ficas e os sintom&#225;ticos com graus variados de disfun&#231;&#227;o ventricular. Existem dist&#250;rbios graves de condu&#231;&#227;o atrioventricular e intraventricular, aqueles com fen&#244;menos tromboemb&#243;licos e com arritmias ventriculares de graus variados<sup>1-4</sup>. Os dist&#250;rbios de condu&#231;&#227;o do est&#237;mulo s&#227;o, sem d&#250;vida, as altera&#231;&#245;es mais frequentes. A altera&#231;&#227;o cl&#225;ssica descrita &#233; o bloqueio completo de ramo direito, associado ou n&#227;o ao bloqueio &#226;ntero-superior do ramo esquerdo<sup>5-6</sup>. Na pr&#225;tica cl&#237;nica, antecedentes sugestivos da doen&#231;a e o encontro deste achado sugerem, de forma significante, a etiologia em nosso meio. O bloqueio de ramo esquerdo (BRE), frequentemente observado na miocardiopatia dilatada, est&#225; presente na cardiopatia chag&#225;sica, mas com incid&#234;ncia muito baixa. Estudos demonstraram um achado de BRE nestes pacientes com ou sem disfun&#231;&#227;o entre zero e 3,1% <sup>2,5</sup>. </p>
    <p>O tempo de evolu&#231;&#227;o da doen&#231;a de Chagas &#233; maior do que em todas as outras etiologias, com dura&#231;&#227;o muitas vezes superior a vinte anos, de forma que o cora&#231;&#227;o pode otimizar todos os mecanismos compensat&#243;rios, mantendo os pacientes assintom&#225;ticos ou oligossintom&#225;ticos por anos ou mesmo d&#233;cadas. Quando o paciente descompensa, &#233; porque o dano mioc&#225;rdico suplantou todos os mecanismos compensat&#243;rios, tornando a doen&#231;a mais grave<sup>1</sup>.</p>
    <p>O progn&#243;stico de forma cr&#244;nica da cardiomiopatia chag&#225;sica est&#225; relacionado ao grau de disfun&#231;&#227;o ventricular avaliado pela fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo (FE), e quanto menor a FE, pior o progn&#243;stico (como em outras cardiomiopatias). Existe tamb&#233;m correla&#231;&#227;o com a classe funcional e o consumo de oxig&#234;nio<sup>1-4</sup>. Al&#233;m disso, a doen&#231;a se mostra mais agressiva em homens, raz&#227;o esta ainda desconhecida<sup>7</sup>.</p>
    <p>Neste paciente, j&#225; na primeira consulta, analisando o ECG e a radiografia de t&#243;rax, observa-se comprometimento mioc&#225;rdico acentuado pela doen&#231;a de Chagas, evidenciado pelo dist&#250;rbio de condu&#231;&#227;o interventricular, baixa amplitude das ondas R e aumento importante da &#225;rea card&#237;aca. Estes achados, associados aos sintomas do paciente, levam-nos a inferir a presen&#231;a de uma miocardiopatia dilatada grave. </p>
    <p>A radiocardiografia realizada no seguimento mostrou hipocinesia acentuada de ventr&#237;culo esquerdo (FE:13%), com discinesia da regi&#227;o &#237;nfero-apical; e de ventr&#237;culo direito (FE:24%), com tronco de art&#233;ria pulmonar abaulada. Confirmando disfun&#231;&#227;o sist&#243;lica acentuada com hipertens&#227;o pulmonar (HP) secund&#225;ria. </p>
    <p>Dos exames laboratoriais, chama aten&#231;&#227;o a hemoglobina elevada (18 g/dl) que pode ser justificada pela hipertens&#227;o pulmonar, e discreto decr&#233;scimo na fun&#231;&#227;o renal possivelmente pelos diur&#233;ticos ou pelo baixo d&#233;bito card&#237;aco.</p>
    <p>O paciente foi submetido a cateterismo card&#237;aco, com medidas das press&#245;es que mostrou hipertens&#227;o pulmonar moderada, sem les&#245;es coron&#225;rias obstrutivas, excluindo assim doen&#231;a arterial coronariana. Houve reversibilidade parcial da HP com nitroprussiato e m&#225;scara e oxig&#234;nio. A resist&#234;ncia vascular pulmonar de 6,3 U Wood foi para 2,2 U Wood. Ainda na investiga&#231;&#227;o da HP foi realizada cintilografia de perfus&#227;o pulmonar com baixa probabilidade de embolia pulmonar.</p>
    <p>Quanto &#224;s complica&#231;&#245;es tromboemb&#243;licas, principalmente para os pulm&#245;es, elas podem ser as primeiras manifesta&#231;&#245;es da doen&#231;a. D&#233;ficits regionais podem determinar tromboses, mesmo com fun&#231;&#227;o global preservada. Pacientes com maior risco s&#227;o aqueles com disfun&#231;&#227;o mioc&#225;rdica grave, fibrila&#231;&#227;o atrial, les&#227;o apical do VE, presen&#231;a de trombos intracavit&#225;rios e embolia pr&#233;via <sup>8</sup>. </p>
    <p>Na evolu&#231;&#227;o, 11 meses ap&#243;s a primeira consulta, o paciente apresentou piora da classe funcional, sendo aumentada a dose do diur&#233;tico. Evoluiu com discreta piora da fun&#231;&#227;o renal. Ap&#243;s dois meses em nova consulta apresentou sintomas de baixo d&#233;bito card&#237;aco, como tonturas e pr&#233;-s&#237;ncope.</p>
    <p>Nesta fase da doen&#231;a, e usando escore elaborado por Rassi e cols.<sup>3</sup> para avaliar risco de &#243;bito em pacientes com doen&#231;a de Chagas, que leva em considera&#231;&#227;o classe funcional III e IV (NYHA) (5 pontos), evid&#234;ncia de cardiomegalia na radiografia de t&#243;rax (5 pontos), disfun&#231;&#227;o sist&#243;lica do VE no ecocardiograma (3 pontos), taquicardia ventricular n&#227;o-sustentada no Holter (3 pontos), baixa voltagem do QRS no ECG (2 pontos) e sexo masculino (2 pontos). Este paciente tem pontua&#231;&#227;o de 17, sendo inclu&#237;do no grupo de alto risco, com mortalidade de 63% em 5 anos e 84% em 10 anos<sup>2</sup>. Portanto este paciente estava evoluindo para estagio D da insufici&#234;ncia card&#237;aca e poder&#237;amos aventar a possibilidade de transplante card&#237;aco. </p>
    <p>O transplante card&#237;aco &#233; indicado para pacientes sintom&#225;ticos com ICC classe III ou IV (NYHA) na vig&#234;ncia de terap&#234;utica medicamentosa adequadamente otimizada com expectativa de vida inferior a um ano e sem possibilidade de outro tratamento cl&#237;nico ou cir&#250;rgico convencional.</p>
    <p>A hipertens&#227;o pulmonar &#233; um fator que impede o transplante card&#237;aco e representa a principal causa de disfun&#231;&#227;o de VD do enxerto no p&#243;s-operat&#243;rio imediato. A resist&#234;ncia vascular pulmonar acima de 2,5 U Woods tem sido apontada como importante fator de risco, considerando-se que a mortalidade aumenta progressivamente acima destas cifras. Assim, neste caso n&#227;o temos contraindica&#231;&#227;o ao transplante card&#237;aco. </p>
    <p>O paciente realizou um ecocardiograma em janeiro de 2007 que evidenciou aumento acentuado de &#225;trio esquerdo (52mm), VE com di&#226;metro diast&#243;lico de 76 e sist&#243;lico de 66 mm, FE de 27%, com press&#227;o sist&#243;lica de art&#233;ria pulmonar de 55 mmHg. </p>
    <p>Na terceira consulta, ap&#243;s redu&#231;&#227;o dos diur&#233;ticos, o paciente evoluiu com melhora dos sintomas, e visando uma avalia&#231;&#227;o para um poss&#237;vel transplante, o paciente foi submetido a uma s&#233;rie de exames. Dentre estes o BNP de 1021 pg/ml chama aten&#231;&#227;o para quadro e insufici&#234;ncia card&#237;aca avan&#231;ada e descompensada apesar da terapia otimizada. </p>
    <p>A ultrassonografia de abdome mostrou aorta ateromatosa e imagens nodulares hiperecog&#234;nicas compat&#237;vel com hemangiomas. </p>
    <p>Em junho de 2008, o paciente apresentou quadro de pneumonia, sendo tratado com levofloxacino, apresentando consequente melhora. Ap&#243;s um m&#234;s, evoluiu com dor precordial persistente com dura&#231;&#227;o de dois dias, que piorava com a inspira&#231;&#227;o profunda e tosse, irradiando para o dorso, al&#233;m de hemoptise e hipotens&#227;o arterial. O eletrocardiograma n&#227;o evidenciou altera&#231;&#245;es em rela&#231;&#227;o ao primeiro e a radiografia de t&#243;rax mostrou imagem sugestiva de infiltrado ret&#237;culo-alveolar difusa nos pulm&#245;es. </p>
    <p>Neste momento, as hip&#243;teses para este quadro s&#227;o hemorragia alveolar secund&#225;ria &#224; hipertens&#227;o pulmonar, broncopneumonia complicada, tuberculose e ao tromboembolismo pulmonar (TEP). Este &#250;ltimo deve sempre estar entre os diagn&#243;sticos diferenciais desses tipos de doentes no atendimento no pronto socorro.</p>
    <p>O diagn&#243;stico cl&#237;nico de TEP &#233; notadamente dificultado por duas raz&#245;es. Primeiro os achados cl&#237;nicos dependem tanto do tamanho do &#234;mbolo quanto do status cardiopulmonar pr&#233;-existente. Segundo, os sintomas e sinais do TEP n&#227;o s&#227;o espec&#237;ficos desta doen&#231;a. Dentre os sintomas, dispneia ocorre em torno de 75% a 85%, dor &#224; inspira&#231;&#227;o em cerca de 65% a 75% e tosse em 53% dos pacientes com TEP. </p>
    <p>Em um estudo<sup>8</sup> que avaliou trombose card&#237;aca e embolia em 111 pacientes falecidos de cardiopatia chag&#225;sica cr&#244;nica do Instituto do Cora&#231;&#227;o foi observado embolia em 60% dos pacientes, dos quais em 65% era pulmonar. A embolia sist&#234;mica esteve presente em 38% dos casos, e o territ&#243;rio renal estava acometido em 70% dos epis&#243;dios. Concluiu-se que a incid&#234;ncia de trombose e embolia &#233; alta nos enfermos com disfun&#231;&#227;o mioc&#225;rdica grave, existindo uma rela&#231;&#227;o entre ambas, embora n&#227;o absoluta. </p>
    <p>Este doente foi submetido &#224; tomografia de t&#243;rax para elucidar os achados da radiografia e esclarecer o diagn&#243;stico.</p>
    <p>A tomografia de t&#243;rax evidenciou linfonodos mediastinais; micron&#243;dulos calcificados esparsos por ambos os pulm&#245;es; n&#243;dulo n&#227;o calcificado de bordas espiculadas medindo 1,6x1,4cm no segmento basal medial do lobo inferior direito; espessamento dos septos interlobulares &#224; direita; opacidade com atenua&#231;&#227;o de vidro fosco predominando nas por&#231;&#245;es m&#233;dias e base do pulm&#227;o direito consolida&#231;&#227;o na base do pulm&#227;o direito. Diante deste resultado, foram feitas as seguintes hip&#243;teses: linfangite pulmonar carcinomatosa, estase ou sarcoidose. A hip&#243;tese de tuberculose foi descartada com culturas de escarro e pesquisa de BAAR negativas. </p>
    <p>A linfangite carcinomatosa &#233; mais comumente originada de neoplasias prim&#225;rias de mama, pulm&#227;o, est&#244;mago, c&#243;lon, pr&#243;stata e p&#226;ncreas. O diagn&#243;stico diferencial deve ser feito com outras doen&#231;as que t&#234;m predile&#231;&#227;o por dissemina&#231;&#227;o linf&#225;tica, como sarcoidose, linfomas, leucemias, paracoccidioidomicose, sarcoma de Kaposi, linfangiomatose pulmonar difusa e linfangiectasia. O aspecto mais frequentemente observado na linfangite carcinomatosa &#233; o espessamento dos septos interlobulares e das bainhas broncovasculares, podendo ser liso ou nodular. Outros achados comuns s&#227;o n&#243;dulos distribu&#237;dos ao longo dos linf&#225;ticos (superf&#237;cie pleural, bainhas broncovasculares, septos interlobulares e regi&#227;o centrolobular). Com frequ&#234;ncia h&#225; derrame pleural associado. Uma caracter&#237;stica importante &#233; a preserva&#231;&#227;o da arquitetura pulmonar normal, sem evid&#234;ncias de distor&#231;&#227;o parenquimatosa (fibrose). Em pacientes com disfun&#231;&#227;o mioc&#225;rdica, principalmente de ventr&#237;culo direito, a diferencia&#231;&#227;o com quadro de congest&#227;o fica dificultada nos exames de imagens. Histologicamente, os achados b&#225;sicos na linfangite carcinomatosa s&#227;o o espessamento dos septos interlobulares e do interst&#237;cio peribroncovascular, por infiltra&#231;&#227;o de c&#233;lulas neopl&#225;sicas dentro dos vasos linf&#225;ticos. Deve-se considerar, contudo, que espessamento intersticial pode tamb&#233;m ocorrer por fibrose, associada a rea&#231;&#227;o desmopl&#225;sica, por edema causado pela obstru&#231;&#227;o linf&#225;tica ou congest&#227;o, ou ainda por uma combina&#231;&#227;o de todos estes fatores<sup>9</sup>.</p>
    <p>A sarcoidose &#233; uma doen&#231;a sist&#234;mica de causa indeterminada, caracterizada por granulomas n&#227;o caseosos. Afeta mais comumente mulheres do que homens, e tem inicio na terceira ou quarta d&#233;cada. Embora possa afetar qualquer &#243;rg&#227;o, esta doen&#231;a tem sua morbi-mortalidade relacionada principalmente ao acometimento pulmonar, presente em 80% a 90% dos pacientes. O padr&#227;o nodular &#233; o mais frequente na sarcoidose pulmonar. Os n&#243;dulos s&#227;o geralmente pequenos e apresentam distribui&#231;&#227;o perilinf&#225;tica, com envolvimento dos feixes peribroncovasculares, septos interlobulares, regi&#245;es centrolobulares subpleurais e ao longo das fissuras. N&#243;dulos cavitados ou de grandes dimens&#245;es, por vezes simulando neoplasias, podem ser encontrados em 15% a 25% dos casos. Outros achados tomogr&#225;ficos na sarcoidose est&#227;o a opacidade em vidro fosco, opacidades parenquimatosas, aprisionamento a&#233;reo, fibrose e bronquiectasias. O diagn&#243;stico necessita demonstra&#231;&#227;o histol&#243;gica de granulomas n&#227;o caseosos na bi&#243;psia<sup>10</sup>.</p>
    <p>A congest&#227;o pulmonar cr&#244;nica por aumento da press&#227;o hidrost&#225;tica pode revelar altera&#231;&#245;es na tomografia do t&#243;rax, como br&#244;nquios de paredes espessadas e aparente aumento do calibre de vasos pulmonares centrais e perif&#233;ricos. Com a manuten&#231;&#227;o do aumento da press&#227;o intersticial h&#225; o aparecimento dos septos interlobulares, que est&#227;o espessados por infiltra&#231;&#227;o l&#237;quida. Outro aspecto encontrado no edema intersticial &#233; a presen&#231;a de opacidades em vidro fosco<sup>11,12</sup>.</p>
    <p>Perante o exposto, e com base na descri&#231;&#227;o da tomografia de t&#243;rax, nenhuma das tr&#234;s hip&#243;teses acima pode ser desconsiderada, visto que ser&#227;o necess&#225;rios dados histol&#243;gicos.</p>
    <p>Na evolu&#231;&#227;o, o paciente recebeu novamente antibi&#243;ticos e dobutamina. Em 07 de julho, apresentou quadro de congest&#227;o pulmonar, que melhorou com medidas cl&#237;nicas, e no dia seguinte sofreu parada cardiorrespirat&#243;ria (PCR) em atividade el&#233;trica sem pulso (AESP), sem sucesso as manobras de reanima&#231;&#227;o.</p>
    <p>Entre as hip&#243;teses de PCR em AESP e de acordo com as considera&#231;&#245;es acima conclu&#237;mos que a causa <italic>mortis</italic> foi tromboembolia pulmonar. </p>
    <p>
      <bold>(Dra. Angela Cristina Matera Bolonhez e Dr. Murilo Capreti Silva)</bold>
    </p>
    <p><bold>Hip&#243;tese diagn&#243;stica principal:</bold> Tromboembolismo Pulmonar; Miocardiopatia Dilatada Chag&#225;sica. </p>
    <p><bold>Outras hip&#243;teses:</bold> Linfangite pulmonar carcinomatosa secund&#225;ria a neoplasia pulmonar prim&#225;ria; congest&#227;o pulmonar cr&#244;nica; e menos prov&#225;vel sarcoidose pulmonar. </p>
    <p>
      <bold>Necr&#243;psia</bold>
    </p>
    <p>O exame morfol&#243;gico do cora&#231;&#227;o constatou cora&#231;&#227;o aumentado de volume, globoso (<xref ref-type="fig" rid="fig06">Figura 6A</xref>), com &#225;reas de espessamento peric&#225;rdico ("manchas l&#225;cteas"), e miocardite cr&#244;nica focal disseminada (<xref ref-type="fig" rid="fig06">Figura 6B</xref>), algumas das caracter&#237;sticas cl&#225;ssicas da forma miocardiopatia chag&#225;sica; por&#233;m n&#227;o havia afilamento da ponta do ventr&#237;culo esquerdo e n&#227;o foram detectados ninhos de <italic>Trypanosoma cruzi</italic> (como, ali&#225;s, frequentemente n&#227;o o s&#227;o).</p>
    <fig id="fig06">
      <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf04.jpg"/></fig>
    <p>No rim e nos pulm&#245;es havia tromboembolismo (<xref ref-type="fig" rid="fig07">Figura 7</xref>), com infarto recente, sendo que o acometimento destes &#250;ltimos foi o fator final desencadeante da morte do paciente. N&#227;o foram encontradas fontes de &#234;mbolos.</p>
    <fig id="fig07">
      <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf05.jpg"/></fig>
    <p>Os pulm&#245;es apresentavam tamb&#233;m adenocarcinoma com dissemina&#231;&#227;o em padr&#227;o miliar para o pr&#243;prio &#243;rg&#227;o, bilateralmente (<xref ref-type="fig" rid="fig08">Figura 8A</xref> e <xref ref-type="fig" rid="fig08">B</xref>). N&#227;o se pode descartar que esta doen&#231;a tenha influenciado a forma&#231;&#227;o de trombos, pois foram vistos vasos com comprometimento neopl&#225;sico nas regi&#245;es de edema e infarto; fala contra essa possibilidade a exist&#234;ncia de co&#225;gulo em vaso renal, levando a infarto, sem neoplasia; mas mesmo a&#237; a trombose pode ser manifesta&#231;&#227;o paraneopl&#225;sica. </p>
    <fig id="fig08">
      <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf06.jpg"/></fig>
    <p>
      <bold>(Dr. Paulo Sampaio Gutierrez)</bold>
    </p>
    <p><bold>Diagn&#243;sticos principais:</bold> 1) Doen&#231;a de Chagas, forma cr&#244;nica card&#237;aca; 2) Adenocarcinoma do pulm&#227;o, com dissemina&#231;&#227;o miliar. </p>
    <p><bold><italic>"Causa mortis"</italic>:</bold> tromboembolismo pulmonar </p>
    <p>
      <bold>(Dr. Paulo Sampaio Gutierrez)</bold>
    </p>
    <p>
      <bold>Coment&#225;rio</bold>
    </p>
    <p>O quadro cl&#237;nico deste paciente, portador de doen&#231;a de Chagas, forma cr&#244;nica card&#237;aca, foi complicado pela associa&#231;&#227;o com adenocarcinoma de pulm&#227;o.</p>
    <p>A associa&#231;&#227;o de doen&#231;a de Chagas com neoplasia &#233; incomum. Entre as 240 necr&#243;psias com essa doen&#231;a infecciosa no Instituto do Cora&#231;&#227;o, os casos, al&#233;m do presente, correspondiam a um paciente com mesotelioma, duas mulheres com hist&#243;ria cl&#237;nica de tratamento pregresso de c&#226;ncer de mama e um linfoma em paciente previamente submetido a transplante card&#237;aco. De toda forma, essa popula&#231;&#227;o n&#227;o &#233; representativa. &#201; muito prov&#225;vel que a doen&#231;a de Chagas, notadamente em sua forma indeterminada, apare&#231;a mais como achado secund&#225;rio em portadores de neoplasias malignas que o contr&#225;rio, representado por nosso material.</p>
    <p>&#201; descrito o surgimento de neoplasias em pacientes submetidos a transplantes. Levantamentos realizados em nosso pa&#237;s evidenciaram que, entre os transplantados card&#237;acos, a incid&#234;ncia de neoplasias foi maior naqueles cujo transplante foi motivado pela doen&#231;a de Chagas<sup>13</sup>, mas n&#227;o houve nenhum relato de neoplasia pulmonar<sup>14</sup>. Os trabalhos sobre a associa&#231;&#227;o entre doen&#231;a de Chagas e neoplasias s&#227;o escassos. Almeida e cols. relatam que a literatura sobre o assunto demonstra que este tema &#233; controverso, e que n&#227;o se verificou aumento ou redu&#231;&#227;o na frequ&#234;ncia de neoplasias malignas em chag&#225;sicos cr&#244;nicos. Indicam ainda que a neoplasia maligna n&#227;o interfere na evolu&#231;&#227;o a curto prazo da cardiopatia<sup>15</sup>. Existem relatos da associa&#231;&#227;o de carcinoma de c&#243;lon com megac&#243;lon chag&#225;sico<sup>16</sup>, mesmo assim alguns autores consideram que este &#250;ltimo talvez seja at&#233; fator de prote&#231;&#227;o para o c&#226;ncer<sup>17</sup>. J&#225; quanto ao megaes&#244;fago, parece haver certa concord&#226;ncia a respeito da rela&#231;&#227;o entre as doen&#231;as, ainda que a incid&#234;ncia encontrada de c&#226;ncer no megaes&#244;fago chag&#225;sico varie, sendo por exemplo relatadas taxas de 3,9% e de 10%<sup>18</sup>.</p>
    <p><bold>Editor da Se&#231;&#227;o:</bold> Alfredo Jos&#233; Mansur (<email xlink:href="ajmansur@incor.usp.br">ajmansur@incor.usp.br</email>) </p>
    <p><bold>Editores Associados:</bold> Desid&#233;rio Favarato (<email xlink:href="dclfavarato@incor.usp.br">dclfavarato@incor.usp.br</email>) </p>
    <p> Vera Demarchi Aiello (<email xlink:href="anpvera@incor.usp.br">anpvera@incor.usp.br</email>)</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Silva CP, Del Carlo CH, Oliveira Junior MT,    Scipioni A, Strunz-Cassaro C, Ramirez JAF, et al. Por que os portadores de cardiomiopatia    chag&#225;sica tem pior evolu&#231;&#227;o que os n&#227;o-chag&#225;sicos?    Arq Bras Cardiol. 2008; 91: 389-94.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Por que os portadores de cardiomiopatia chag&#225;sica tem pior evolu&#231;&#227;o que os n&#227;o-chag&#225;sicos?</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>389</fpage>
          <lpage>94</lpage>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Silva</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Del Carlo</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Oliveira Junior</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Scipioni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Strunz-Cassaro</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ramirez</surname>
              <given-names>JAF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Mady C, Cardoso RH, Barretto AC, Luz PL, Bellotti    G, Pileggi F. Survival and predictors of survival in patients with congestive    heart failure due to Chagas' cardiomyopathy, Circulation. 1994; 90: 3098-102.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Survival and predictors of survival in patients with congestive heart failure due to</article-title>
          <source>Chagas' cardiomyopathy, Circulation</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>3098</fpage>
          <lpage>102</lpage>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cardoso</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Luz</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Bellotti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pileggi</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Rassi A Jr, Rassi A, Little WC, Xavier SS,    Rassi SG, Rassi AG, et al. Development and validation of a risk score for predicting    death in Chagas' heart disease. N Engl J Med. 2006; 355: 799-808.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Development and validation of a risk score for predicting death in Chagas' heart disease</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>799</fpage>
          <lpage>808</lpage>
          <volume>355</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rassi Jr</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rassi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Little</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Xavier</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Rassi</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Rassi</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Freitas HF, Chizzola PR, Paes AT, Lima AC,    Mansur AJ. Risk stratification in a brazilian hospital-based cohort of 1220    outpatients with heart failure: role of Chagas' heart disease. Int J Cardiol.    2005; 102: 239-47.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Risk stratification in a brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>239</fpage>
          <lpage>47</lpage>
          <volume>102</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Freitas</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Chizzola</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Paes</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Mansur</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Ianni BM, Arteaga E, Frimm CC, Barretto AC,    Mady C. Chagas' heart disease: evolutive evaluation of electrocardiographic    and echocardiographic parameters in patients with the indeterminate form. Arq    Bras Cardiol. 2001; 77: 59-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chagas' heart disease: evolutive evaluation of electrocardiographic and echocardiographic parameters in patients with the indeterminate form</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>59</fpage>
          <lpage>62</lpage>
          <volume>77</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ianni</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Arteaga</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Frimm</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Barretto AC, Bellotti G, Deperon SD, Arteaga-Fern&#225;ndez    E, Mady C, Ianni BM, Pileggi F. O valor do eletrocardiograma na avalia&#231;&#227;o    da fun&#231;&#227;o mioc&#225;rdica dos portadores de doen&#231;a de    Chagas. Arq Bras Cardiol. 1989; 52: 69-73.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>O valor do eletrocardiograma na avalia&#231;&#227;o da fun&#231;&#227;o mioc&#225;rdica dos portadores de doen&#231;a de Chagas</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1989</year>
          </date>
          <fpage>69</fpage>
          <lpage>73</lpage>
          <volume>52</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Bellotti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Deperon</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Arteaga-Fern&#225;ndez</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ianni</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Pileggi</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Barretto AC, Arteaga E, Mady C, Ianni BM,    Bellotti G, Pileggi F. Sexo masculino: fator progn&#243;stico na doen&#231;a    de Chagas. Arq Bras Cardiol. 1993; 60: 225-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sexo masculino: fator progn&#243;stico na doen&#231;a de Chagas</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>225</fpage>
          <lpage>6</lpage>
          <volume>60</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Arteaga</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ianni</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Bellotti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pileggi</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Arteaga-Fernadez E, Barretto ACP, Ianni BM,    Mady C, Lopes EA, Vianna C, et al. Trombose card&#237;aca e embolia em pacientes    falecidos de cardiopatia chag&#225;sica cr&#244;nica. Arq Bras Cardiol. 1989;    52: 189-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Trombose card&#237;aca e embolia em pacientes falecidos de cardiopatia chag&#225;sica cr&#244;nica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1989</year>
          </date>
          <fpage>189</fpage>
          <lpage>92</lpage>
          <volume>52</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Arteaga-Fernadez</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Barretto</surname>
              <given-names>ACP</given-names>
            </name>
            <name>
              <surname>Ianni</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Vianna</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Marchiori E, Irion K, Souza Jr AS. Neoplasias    pulmonares difusas: correla&#231;&#227;o da tomografia computadorizada de    alta resolu&#231;&#227;o com a anatomopatologia. Radiol Bras. 2002; 35:    225-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Neoplasias pulmonares difusas: correla&#231;&#227;o da tomografia computadorizada de alta resolu&#231;&#227;o com a anatomopatologia</article-title>
          <source>Radiol Bras</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>225</fpage>
          <lpage>33</lpage>
          <volume>35</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Marchiori</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Irion</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Souza Jr</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. N&#243;brega BB, Meirelles GSP, Szarf G,    Kavakama JI. Sarcoidose pulmonar: achados na tomografia de t&#243;rax de alta    resolu&#231;&#227;o. J Bras Pneumol. 2005; 31: 254-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sarcoidose pulmonar: achados na tomografia de t&#243;rax de alta resolu&#231;&#227;o</article-title>
          <source>J Bras Pneumol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>254</fpage>
          <lpage>60</lpage>
          <volume>31</volume>
          <person-group person-group-type="author">
            <name>
              <surname>N&#243;brega</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Meirelles</surname>
              <given-names>GSP</given-names>
            </name>
            <name>
              <surname>Szarf</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kavakama</surname>
              <given-names>JI</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Ribeiro CMC, Marchiori E, Rodrigues R, Gasparetto    E, Souza Jr AS, Escuissato D, et al. Edema pulmonar hidrost&#225;tico: aspectos    na tomografia computadorizada de alta resolu&#231;&#227;o. J Bras Pneumol.    2006; 32: 15-22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Edema pulmonar hidrost&#225;tico: aspectos na tomografia computadorizada de alta resolu&#231;&#227;o</article-title>
          <source>J Bras Pneumol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>15</fpage>
          <lpage>22</lpage>
          <volume>32</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ribeiro</surname>
              <given-names>CMC</given-names>
            </name>
            <name>
              <surname>Marchiori</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gasparetto</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Souza Jr</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Escuissato</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Storto M, Kee ST, Golden JA, Webb WR. Hydrostatic    pulmonary edema: high-resolution CT findings. AJR Am J Roentgenol. 1995; 165:    817-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hydrostatic pulmonary edema: high-resolution CT findings</article-title>
          <source>AJR Am J Roentgenol</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>817</fpage>
          <lpage>20</lpage>
          <volume>165</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Storto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kee</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Golden</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>WR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Bocchi EA, Fiorelli A. The paradox of survival    results after heart transplantation for cardiomyopathy caused by Trypanosoma    cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society    of Cardiology. Ann Thorac Surg. 2001; 71 (6): 1833-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology</article-title>
          <source>Ann Thorac Surg</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1833</fpage>
          <lpage>8</lpage>
          <issue>6</issue>
          <volume>71</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Fiorelli</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Fiorelli AI, Stolf NA, Honorato R, Bocchi    E, Bacal F, Uip D, et al. Later evolution after cardiac transplantation in Chagas'    disease. Transplant Proc. 2005; 37: 2793-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Later evolution after cardiac transplantation in Chagas' disease</article-title>
          <source>Transplant Proc</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>2793</fpage>
          <lpage>8</lpage>
          <volume>37</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fiorelli</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Stolf</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Honorato</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bocchi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bacal</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Uip</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Almeida EA, Figueiredo DM, Guariento ME,    Souza ML, Wanderley JS. Estudo do perfil cl&#237;nico e evolutivo de indiv&#237;duos    com a doen&#231;a de Chagas cr&#244;nica e neoplasias malignas. Rev Soc Bras    Clin Med. 2008; 6: 1-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Estudo do perfil cl&#237;nico e evolutivo de indiv&#237;duos com a doen&#231;a de Chagas cr&#244;nica e neoplasias malignas</article-title>
          <source>Rev Soc Bras Clin Med</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <volume>6</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Almeida</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Figueiredo</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Guariento</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Souza</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Wanderley</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Adad SJ, Etchebehere RM, Ara&#250;jo JR,    Madureira AB, Lima VG, Silva AA, et al. Associa&#231;&#227;o de megac&#243;lon    chag&#225;sico e c&#226;ncer de c&#243;lon: relato de caso e revis&#227;o    da literatura. Rev Soc Bras Med Trop. 2002; 35: 63-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Associa&#231;&#227;o de megac&#243;lon chag&#225;sico e c&#226;ncer de c&#243;lon: relato de caso e revis&#227;o da literatura</article-title>
          <source>Rev Soc Bras Med Trop</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>63</fpage>
          <lpage>8</lpage>
          <volume>35</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Adad</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Etchebehere</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Ara&#250;jo</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Madureira</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>VG</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Garcia SB, Aranha AL, Garcia FR, Basile FV,    Pinto AP, de Oliveira EC, et al. Um estudo retrospectivo dos achados histopatol&#243;gicos    em 894 casos de megac&#243;lon: qual &#233; a rela&#231;&#227;o entre    megac&#243;lon e o c&#226;ncer de c&#243;lon? Rev Inst Med Trop S&#227;o    Paulo. 2003; 45: 91-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Um estudo retrospectivo dos achados histopatol&#243;gicos em 894 casos de megac&#243;lon: qual &#233; a rela&#231;&#227;o entre megac&#243;lon e o c&#226;ncer de c&#243;lon?</article-title>
          <source>Rev Inst Med Trop S&#227;o Paulo</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>91</fpage>
          <lpage>3</lpage>
          <volume>45</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Garcia</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Aranha</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Basile</surname>
              <given-names>FV</given-names>
            </name>
            <name>
              <surname>Pinto</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>de Oliveira</surname>
              <given-names>EC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Henry MA, Lerco MM, Oliveira WK. C&#226;ncer    do es&#244;fago em paciente com megaes&#244;fago chag&#225;sico. Arq Gastroenterol.    2007; 44: 151-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>C&#226;ncer do es&#244;fago em paciente com megaes&#244;fago chag&#225;sico</article-title>
          <source>Arq Gastroenterol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>151</fpage>
          <lpage>5</lpage>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Henry</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Lerco</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>WK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Caso 4/2009: var&#243;n de 55 a&#241;os con cardiomiopat&#237;a de la enfermedad de Chagas que evolucion&#243; con disnea progresiva, dolor tor&#225;cico e infiltrado intersticial pulmonar</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>
        <bold>CORRELACI&#211;N ANATOMOCL&#205;NICA</bold>
      </p>
      <p>
        <fn id="tx-body2">
          <label>
            <bold>Caso 4/2009 - Var&#243;n de 55 a&#241;os con cardiomiopat&#237;a de la enfermedad de Chagas que evolucion&#243; con disnea progresiva, dolor tor&#225;cico e infiltrado intersticial pulmonar</bold>
          </label>
          <p>
            <bold>Angela Cristina Matera Bolonhez; Murilo Capreti da Silva; Rodrigo Caruso Chate; Paulo Sampaio Gutierrez</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o (InCor) HC-FMUSP, S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p><bold>Palabras clave: </bold> Enfermedad de Chagas, disnea, bloqueo de rama, disfunci&#243;n ventricular.</p>
      <p>Var&#243;n de 55 a&#241;os de edad, alba&#241;il jubilado, natural de Itapetim (PE) requiri&#243; atenci&#243;n m&#233;dica en raz&#243;n de falta de aire (4/11/2005). </p>
      <p>Refiere que desde hace tres a&#241;os viene presentando disnea de intensidad progresiva, desencadenada a principio por grandes esfuerzos. Desde hace un a&#241;o viene presentando falta de aire con esfuerzos moderados, asociada a palpitaciones taquic&#225;rdicas. Requiri&#243; atenci&#243;n m&#233;dica en Unidad B&#225;sica de Salud, recibi&#243; prescripci&#243;n de medicamentos de los que no se acuerda. Mejor&#243; tras hacer uso de ellos. Recibi&#243; informaci&#243;n previa de ser portador de enfermedad de Chagas.</p>
      <p>El paciente hac&#237;a uso de carvedilol 3,125 mg dos veces al d&#237;a y, diariamente, de digoxina 0,25 mg, espironolactona 25 mg, &#225;cido acetilsalic&#237;lico 100 mg, hidroclorotiazida 25mg asociada a amilorida 2,5 mg &#189; cp. </p>
      <p>El examen f&#237;sico revel&#243; peso de 74,8 kg, altura de 1,64 m, &#237;ndice de masa corp&#243;rea 27,8 kg/m<sup>2</sup>, pulso de 78 latidos por minuto, presi&#243;n arterial de 110/80 mmHg. El examen de los pulmones estaba normal. El examen del coraz&#243;n revel&#243; ruidos r&#237;tmicos, ruidos normales, sin ruidos accesorios, sin estallidos o soplos cardiacos. El examen del abdomen fue normal. No hab&#237;a edema de miembros. </p>
      <p>El electrocardiograma (1/11/2005) revel&#243; ritmo sinusal y ondas R de baja amplitud en derivaciones de extremidades y en derivaciones precordiales, adem&#225;s de disturbio de la conducci&#243;n intraventricular del est&#237;mulo y sobrecarga ventricular y atrial izquierdos (<xref ref-type="fig" rid="fig01-body2">Figura 1</xref>).</p>
      <fig id="fig01-body2">
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf01-es.jpg"/></fig>
      <p>La radiograf&#237;a de t&#243;rax revel&#243; cardiomegalia +++/4. </p>
      <p>Se llev&#243; a cabo el diagn&#243;stico de insuficiencia cardiaca por cardiomiopat&#237;a de la enfermedad de Chagas. </p>
      <p>Se hizo el ajuste de la medicaci&#243;n con suspensi&#243;n del &#225;cido acetilsalic&#237;lico y la asociaci&#243;n hidroclorotiazida/amilorida, aumento de la dosis de carvedilol para 6,25 mg 2x/d&#237;a, a&#241;adiendo tambi&#233;n enalapril 10 mg 2x/d&#237;a.</p>
      <p>La prueba para detecci&#243;n de anticuerpos anti <italic>Trypanosoma cruzi</italic> (3/11/2005) evidenci&#243; suero reactivo.</p>
      <p>El radiocardiograma ("gated blood pool") (14/6/2006) con hemat&#237;es marcadas con <sup>99m</sup>Tecn&#233;cio revel&#243; ritmo de blanqueamiento ventricular del trazador alterado bilateralmente y tronco de arteria pulmonar abombado. El tiempo promedio de transito pulmonar fue superior a 20 segundos. El atrio y el ventr&#237;culo derechos se hallaron aumentados de volumen. Hab&#237;a hipocinesia difusa acentuada del ventr&#237;culo derecho. El ventr&#237;culo izquierdo estaba aumentado en grado acentuado y hab&#237;a hipocinesia difusa acentuada y discinesia de la regi&#243;n inferoapical del ventr&#237;culo izquierdo. La regi&#243;n inferoapical del ventr&#237;culo izquierdo se mov&#237;a en oposici&#243;n de fase con relaci&#243;n a las dem&#225;s paredes. La fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo se estim&#243; en el 13% y del ventr&#237;culo derecho en el 24%.</p>
      <p>La evaluaci&#243;n laboratorial (13/07/2006) revel&#243; hemoglobina 18,1 g/dl, hematocrito el 54%, VCM 100 fl, CHCM 34 g/dl, 5400000 eritrocitos por mm<sup>3</sup>, 6900 leucocitos por mm<sup>3</sup> (neutrofilos el 72%, eosinofilos el 2%, linfocitos el 18%, monocitos el 8%), sodio 137 mEq/l, potasio 5,1 mEq/l, urea 82 mg/dl, creatinina 1,1 mg/dl, aspartato aminotransferasa 36 U/l alanina aminotransferasa 56 U/l, &#225;cido &#250;rico 7,3 mg/dl, alb&#250;mina 3,7 g/dl, bilirrubina total 1,36 mg/dl (directa 0,68 mg/dl, indirecta 0,68 mg/dl), tiempo de protrombina 19,3 seg (INR 1,45), proteinuria de 24 h 0,14g (normal hasta 0,15). El examen parasitol&#243;gico de heces (Hoffman, Rugai) fue negativo, ant&#237;geno carcinoembrionario 2,8 ng/ml (referencia hasta 5,0 ng/ml).</p>
      <p>Se someti&#243; al paciente a cateterismo card&#237;aco, (3/8/2006) el que revel&#243; hipertensi&#243;n pulmonar moderada (<xref ref-type="table" rid="tab01-body2">Tabla 1</xref>), y que no evidenci&#243; lesiones obstructivas en arterias coronarias. </p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gt01-es.jpg"/></table-wrap>
      <p>El centellograma pulmonar por ventilaci&#243;n/perfusi&#243;n (12/9/2006) se consider&#243; como de baja probabilidad el riesgo de embolia pulmonar. </p>
      <p>El 6/10/2006, el paciente se quej&#243; de cansancio a los esfuerzos y de edema de miembros inferiores. Se aument&#243; la dosis de los diur&#233;ticos para furosemida 80 mg, diarios, adem&#225;s de la medicaci&#243;n que &#233;l ya ven&#237;a recibiendo.</p>
      <p>El 3/11/2006, la urea fue de 81 mg/dl, la creatinina fue de 1,55 mg/dl y el potasio s&#233;rico de 4,9 mEq/l.</p>
      <p>En uno de los retornos ambulatorios (4/12/2006) el individuo se quej&#243; de falta de aire, episodios de v&#233;rtigo y desde hace 15 d&#237;as con pre s&#237;ncope. Manifest&#243; queja tambi&#233;n de hinchaz&#243;n en las piernas y en el abdomen. Ven&#237;a en uso de hidralazina 25 mg 2x/d&#237;a, furosemida 40 mg 2x/d&#237;a, adem&#225;s de la espironolactona, carvedilol, enalapril y digoxina. Se orient&#243; para ajuste de dieta, actividad y medicaci&#243;n: se reduzco la dosis de diur&#233;ticos. </p>
      <p>El ecocardiograma (3/1/2007) revel&#243; aorta 32 mm, atrio izquierdo 52 mm, ventr&#237;culo derecho 30 mm, septo interventricular 8 mm, pared posterior de ventr&#237;culo izquierdo 8 mm, di&#225;metro diast&#243;lico del ventr&#237;culo izquierdo 76 mm, di&#225;metro sist&#243;lico del ventr&#237;culo izquierdo 66 mm, fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo (Teicholz) el 27%. El estudio con Doppler revel&#243; est&#225;ndares de flujo compatibles con est&#225;ndar restrictivo, con reversi&#243;n tras maniobra de Valsalva. Se consideraron las v&#225;lvulas cardiacas como normales. La presi&#243;n sist&#243;lica en la arteria pulmonar se estim&#243; en 55 mmHg. </p>
      <p>Despu&#233;s del ajuste de la medicaci&#243;n en diciembre, hubo mejora de los s&#237;ntomas (12/1/2007).</p>
      <p>La evaluaci&#243;n laboratorial en la evoluci&#243;n revel&#243; glucemia de ayuno 106 mg/dl (18/9/2007), p&#233;ptido natriur&#233;tico tipo B 1021 pg/ml (referencia: &lt;100 pg/ml), colesterol 220 mg/dl, HDL-colesterol 39 mg/dl, LDL-colesterol 157 mg/dl, TSH 2,87 mUI/ml, T<sub>4</sub> libre1,7 ng/dl, glucemia 106 mg/dl y la hemoglobina glicosilada el 6,1%, CA 19,9 2,6 U/ml (referencia hasta 37 U/ml) (29/10/2007).</p>
      <p>El ultrasonido de abdomen (12/5/2008) revel&#243; aorta ateromatosa e im&#225;genes nodulares hiperecog&#233;nicas hep&#225;ticas que se consideraron compatibles con hemangiomas. </p>
      <p>El 3/6/2008, el paciente present&#243; tos con expectoraci&#243;n color amarillo, adem&#225;s de la disnea. Busc&#243; atenci&#243;n en una Unidad B&#225;sica de Salud, tras medicado con levofloxacina 500 mg 1x/d&#237;a. Se observ&#243; una mejora cl&#237;nica. </p>
      <p>En la evoluci&#243;n, requiri&#243; atenci&#243;n m&#233;dica (3/7/2008) por culpa de dolor precordial persistente a 2 d&#237;as, que empeoraba con la inspiraci&#243;n profunda o con la tos, que se irradiaba hacia el dorso, adem&#225;s de tos con expectoraci&#243;n sanguinolenta. </p>
      <p>Hac&#237;a tratamiento diario con carvedilol 50 mg, enalapril 40 mg, digoxina 0,125 mg, furosemida 40 mg, hidroclorotiazida 25 mg, espironolactona 25 mg y omeprazol. </p>
      <p>El examen f&#237;sico revel&#243; pulso de 80 latidos por minuto, presi&#243;n arterial de 80/40 mmHg. En el restante del examen f&#237;sico no hab&#237;a registro de datos diagn&#243;sticos. </p>
      <p>El 3/7/2008, el electrocardiograma no evidenci&#243; alteraci&#243;n significativa con relaci&#243;n al electrocardiograma anterior. </p>
      <p>La radiograf&#237;a de t&#243;rax (3/7/2008) revel&#243; imagen sugestiva de infiltrado ret&#237;culo alveolar difuso en los pulmones.</p>
      <p>La tomograf&#237;a de t&#243;rax (3/7/2008) revel&#243; estructuras vasculares mediast&#237;nicas de calibre normal y contornos regulares, cardiomegalia, linfonodos mediast&#237;nicos menores que 10 mm, micron&#243;dulos calcificados esparcidos por ambos pulmones, n&#243;dulo no calcificado, de bordes afilados que miden 1,6 x 1,4cm en el segmento basal medial del LID, micron&#243;dulos de distribuci&#243;n centrolobular difusos por ambos pulmones y espesor de septos interlobulares a la derecha. Opacidad con atenuaci&#243;n en vidrio fosco predominando en las porciones medias y base del pulm&#243;n derecho, consolidaci&#243;n en la base del pulm&#243;n derecho. </p>
      <p>Se llevaron a cabo las hip&#243;tesis diagn&#243;sticas de linfangitis, estasis o sarcoidosis. </p>
      <p>La cultura de esputo para micobact&#233;rias y la investigaci&#243;n de bacilos alcohol-&#225;cido resistentes (4/7/2009) fueron negativas. </p>
      <p>Se le medic&#243; al paciente con claritromicina 500 mg v&#237;a endovenosa a cada 12 horas, ceftriaxona 1g v&#237;a endovenosa a cada 12 horas, adem&#225;s de la medicaci&#243;n cardiovascular de que hac&#237;a uso. Se asoci&#243; a la administraci&#243;n de dobutamina.</p>
      <p>El 7/7/2008, present&#243; cuadro descrito como edema agudo de pulm&#243;n, que mejor&#243; con el uso de diur&#233;ticos, ventilaci&#243;n no invasiva y vasodilatadores.</p>
      <p>El d&#237;a siguiente, el 8/7/2008, sufri&#243; parada cardiaca en actividad el&#233;ctrica sin pulso, no revertida con maniobras de reanimaci&#243;n. </p>
      <p>
        <bold>Comentarios - Radi&#243;logo de t&#243;rax del InCor</bold>
      </p>
      <p>En la tomograf&#237;a de t&#243;rax llevada a cabo sin contraste iodado intravenoso, se identificaba n&#243;dulo pulmonar no calcificado, de contornos lobulados, en el lobo inferior derecho, cuyo aspecto tomogr&#225;fico favorec&#237;a la posibilidad de neoplasia primaria (<xref ref-type="fig" rid="fig02-body2">Figura 2</xref>). En el pulm&#243;n derecho, se hallaba asociado el espesor de los intersticios peribroncovascular y septal, por veces con aspecto liso y en algunas regiones con est&#225;ndar micronodular, levantando la posibilidad de linfangitis carcinomatosa (<xref ref-type="fig" rid="fig02-body2">Figuras 2 a 4</xref>). Todav&#237;a estaban destacados m&#250;ltiples peque&#241;os n&#243;dulos no calcificados diseminados por todos los campos pulmonares, que, en este contexto cl&#237;nico, son compatibles con lesiones secundarias (<xref ref-type="fig" rid="fig02-body2">Figuras 2 a 4</xref>). Los cortes tomogr&#225;ficos revelaban a&#250;n focos de consolidaci&#243;n pulmonar con base pleural esparcidos bilateralmente - adem&#225;s de opacidades en vidrio fosco que los circundaban -, predominando en los segmentos basales del lobo inferior derecho (<xref ref-type="fig" rid="fig05-body2">Figura 5</xref>), consistentes con &#225;reas de infarto y hemorragia pulmonar en el contexto cl&#237;nico de tromboembolismo agudo. </p>
      <fig id="fig02-body2">
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf02-es.jpg"/></fig>
      <p>
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-e01-es.jpg"/></p>
      <p>
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-e02-es.jpg"/></p>
      <fig id="fig05-body2">
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf03-es.jpg"/></fig>
      <p>
        <bold>Dr. Rodrigo Caruso Chate</bold>
      </p>
      <p>
        <bold>Aspectos cl&#237;nicos</bold>
      </p>
      <p>Se trata de un paciente del sexo masculino, 55 a&#241;os de edad, que en noviembre de 2005 requiri&#243; atenci&#243;n por disnea con empeoramiento progresivo desde hab&#237;a 3 a&#241;os, asociada a palpitaciones taquic&#225;rdicas, con serolog&#237;a positiva para enfermedad de Chagas. El examen f&#237;sico fue normal, el electrocardiograma (ECG) mostr&#243; bloqueo de rama izquierda y ondas R de baja amplitud, y la radiograf&#237;a de t&#243;rax evidenci&#243; aumento de &#225;rea cardiaca (cardiomegalia 3+/4+), compatible con insuficiencia cardiaca de probable etiolog&#237;a por enfermedad de Chagas, en su forma de miocardiopat&#237;a cr&#243;nica dilatada. El paciente hac&#237;a uso de bajas dosis de carvedilol adem&#225;s de digoxina, &#225;cido acetilsalic&#237;lico, espironolactona, hidroclorotiazida y amilorida. Se ajustaron las medicaciones con introducci&#243;n de inhibidor de la enzima conversora de la angiotensina (enalapril) y tuvo inicio el seguimiento.</p>
      <p>Fue posible efectuar algunas consideraciones respecto a la etiolog&#237;a de la insuficiencia cardiaca. La enfermedad de Chagas en su forma cr&#243;nica se caracterizaba por la diversidad. Hay pacientes asintom&#225;ticos en la forma indeterminada, los asintom&#225;ticos con alteraciones electrocardiogr&#225;ficas y los sintom&#225;ticos con grados variados de disfunci&#243;n ventricular. Hay disturbios severos de conducci&#243;n atrioventricular e intraventricular, aquellos con fen&#243;menos tromboemb&#243;licos y con arritmias ventriculares de grados variados<sup>1-4</sup>. Los disturbios de conducci&#243;n del est&#237;mulo son, sin duda, las alteraciones m&#225;s frecuentes. La alteraci&#243;n cl&#225;sica descrita es el bloqueo completo de la rama derecha, asociado o no al bloqueo anterosuperior de la rama izquierda<sup>5-6</sup>. En la pr&#225;ctica cl&#237;nica, antecedentes sugestivos de la enfermedad y el encuentro de este hallazgo sugieren, de forma significante, la etiolog&#237;a en nuestro medio. El bloqueo de rama izquierda (BRE), frecuentemente observado en la miocardiopat&#237;a dilatada, est&#225; presente en la cardiopat&#237;a chag&#225;sica, sin embargo con incidencia muy baja. Estudios revelaron un hallazgo de BRE en estos pacientes con o sin disfunci&#243;n entre cero y 3,1%<sup>2,5</sup>. </p>
      <p>El tiempo de evoluci&#243;n de la enfermedad de Chagas es mayor que en todas las otras etiolog&#237;as, con duraci&#243;n muchas veces superior a 20 a&#241;os, de modo que el coraz&#243;n puede optimizar todos los mecanismos compensatorios, manteniendo a los pacientes asintom&#225;ticos u oligosintom&#225;ticos durante a&#241;os o incluso d&#233;cadas. Cuando el paciente descompensa, es porque el da&#241;o mioc&#225;rdico suplant&#243; todos los mecanismos compensatorios, convirtiendo la enfermedad en m&#225;s severa<sup>1</sup>.</p>
      <p>El pron&#243;stico de forma cr&#243;nica de la cardiomiopat&#237;a chag&#225;sica se halla relacionado al grado de disfunci&#243;n ventricular evaluado por la fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo (FE), y cuanto menor la FE, peor el pron&#243;stico (como en otras cardiomiopat&#237;as). Hay asimismo correlaci&#243;n con la clase funcional y el consumo de ox&#237;geno<sup>1-4</sup>. Adem&#225;s de eso, la enfermedad se muestra m&#225;s agresiva en varones, raz&#243;n esta todav&#237;a desconocida<sup>7</sup>.</p>
      <p>En este paciente, ya en la primera consulta, al analizar el ECG y la radiograf&#237;a de t&#243;rax, se pudo observar compromiso mioc&#225;rdico acentuado en raz&#243;n de la enfermedad de Chagas, evidenciado por el disturbio de conducci&#243;n interventricular, de la baja amplitud de las ondas R y aumento importante del &#225;rea cardiaca. Estos hallazgos, asociados a los s&#237;ntomas del paciente, nos llevan a inferir la presencia de una miocardiopat&#237;a dilatada severa. </p>
      <p>La radiocardiograf&#237;a realizada en el seguimiento evidenci&#243; hipocinesia acentuada de ventr&#237;culo izquierdo (FE:13%), con discinesia de la regi&#243;n inferoapical; y de ventr&#237;culo derecho (FE:24%), con tronco de arteria pulmonar abombada. As&#237; que se confirm&#243; disfunci&#243;n sist&#243;lica acentuada con hipertensi&#243;n pulmonar (HP) secundaria. </p>
      <p>Teniendo en cuenta los ex&#225;menes laboratoriales, nos llama la atenci&#243;n la hemoglobina elevada (18g/dl) que se puede justificar mediante la hipertensi&#243;n pulmonar, y por el discreto descenso en la funci&#243;n renal posiblemente por los diur&#233;ticos o debido al bajo gasto cardiaco.</p>
      <p>El paciente se someti&#243; a cateterismo cardiaco, con mediciones de las presiones que revel&#243; hipertensi&#243;n pulmonar moderada, sin lesiones coronarias obstructivas, lo que excluy&#243; la enfermedad arterial coronaria. Hubo reversibilidad parcial de la HP con nitroprusiato y m&#225;scara y ox&#237;geno. La resistencia vascular pulmonar de 6,3 U Wood fue para 2,2 U Wood. Todav&#237;a en la investigaci&#243;n de la HP se realiz&#243; centellograf&#237;a de perfusi&#243;n pulmonar con baja probabilidad de embolia pulmonar.</p>
      <p>En cuanto a las complicaciones tromboemb&#243;licas, principalmente para los pulmones, ellas pueden ser las primeras manifestaciones de la enfermedad. Los d&#233;ficits regionales pueden determinar trombosis, incluso con funci&#243;n global preservada. Pacientes con mayor riesgo son aquellos con disfunci&#243;n mioc&#225;rdica severa, fibrilaci&#243;n atrial, lesi&#243;n apical del VI, presencia de trombos intracavitarios y embolia previa<sup>8</sup>. </p>
      <p>En la evoluci&#243;n, 11 meses tras la primera consulta, el paciente present&#243; empeoramiento de la clase funcional, siendo aumentada la dosis del diur&#233;tico. Evolucion&#243; con discreto empeoramiento de la funci&#243;n renal. Despu&#233;s de dos meses en nueva consulta present&#243; s&#237;ntomas de bajo gasto cardiaco, como v&#233;rtigos y pres&#237;ncope.</p>
      <p>En esta fase de la enfermedad, y con la utilizaci&#243;n del score elaborado por Rassi et al<sup>3</sup> para evaluar el riesgo de &#243;bito en pacientes con enfermedad de Chagas, que toma en consideraci&#243;n la clase funcional III y IV (NYHA) (5 puntos), evidencia de cardiomegalia en la radiograf&#237;a de t&#243;rax (5 puntos), disfunci&#243;n sist&#243;lica del VI en el ecocardiograma (3 puntos), taquicardia ventricular no sostenida en el Holter (3 puntos), bajo voltaje del QRS en el ECG (2 puntos) y sexo masculino (2 puntos). Este paciente tiene una puntuaci&#243;n de 17, y se incluye en el grupo de alto riesgo, con mortalidad del 63% en 5 a&#241;os y el 84% en 10 a&#241;os<sup>2</sup>. Por lo tanto, este paciente estaba evolucionando hacia el estadio D de la insuficiencia cardiaca y se podr&#237;a aventar la posibilidad de transplante card&#237;aco. </p>
      <p>El transplante cardiaco se recomienda a pacientes sintom&#225;ticos con ICC clase III o IV (NYHA) en la vigencia de terap&#233;utica medicamentosa adecuadamente optimizada con expectativa de vida inferior a un a&#241;o y sin posibilidad de otro tratamiento cl&#237;nico o quir&#250;rgico convencional.</p>
      <p>La hipertensi&#243;n pulmonar es un factor que impide el transplante cardiaco y representa la principal causa de disfunci&#243;n de VD del injerto en el postoperatorio inmediato. La resistencia vascular pulmonar superior a 2,5 U Woods viene siendo se&#241;alada como un importante factor de riesgo, teniendo en cuenta que la mortalidad aumenta progresivamente arriba de estos valores. As&#237;, en este caso, no hay contraindicaci&#243;n para el transplante cardiaco. </p>
      <p>El paciente realiz&#243; un ecocardiograma en enero de 2007 que evidenci&#243; aumento acentuado de atrio izquierdo (52mm), VI con di&#225;metro diast&#243;lico de 76 y sist&#243;lico de 66 mm, FE del 27%, con presi&#243;n sist&#243;lica de arteria pulmonar de 55 mm Hg. </p>
      <p>En la tercera consulta, tras reducci&#243;n de los diur&#233;ticos, el paciente evolucion&#243; con mejora de los s&#237;ntomas, y al buscar una evaluaci&#243;n para un posible transplante, el paciente se someti&#243; a una serie de ex&#225;menes. Entre &#233;stos, el BNP de 1021 pg/ml llama la atenci&#243;n para cuadro e insuficiencia cardiaca avanzada y descompensada a pesar de la terapia optimizada.</p>
      <p>El ultrasonido de abdomen revel&#243; aorta ateromatosa e im&#225;genes nodulares hiperecog&#233;nicas compatibles con hemangiomas. </p>
      <p>En junio de 2008, el paciente present&#243; cuadro de neumon&#237;a, y se trat&#243; con levofloxacino, presentando consecuente mejora. Tras un mes, evolucion&#243; con dolor precordial persistente con duraci&#243;n de dos d&#237;as, que empeoraba con la inspiraci&#243;n profunda y tos, irradiando hacia el dorso, adem&#225;s de hemoptisis e hipotensi&#243;n arterial. El electrocardiograma no evidenci&#243; alteraciones con relaci&#243;n al primero y la radiograf&#237;a de t&#243;rax revel&#243; una imagen sugestiva de infiltrado ret&#237;culo-alveolar difusa en los pulmones. </p>
      <p>En este momento, las hip&#243;tesis para este cuadro son hemorragia alveolar secundaria a la hipertensi&#243;n pulmonar, bronconeumon&#237;a complicada, tuberculosis y al tromboembolismo pulmonar (TEP). Este &#250;ltimo debe siempre estar entre los diagn&#243;sticos diferenciales de esos tipos de enfermos en la atenci&#243;n en el hospital de urgencias.</p>
      <p>Dos razones dificultan notadamente el diagn&#243;stico cl&#237;nico de TEP. Primero, los hallazgos cl&#237;nicos dependen tanto del tama&#241;o del &#233;mbolo como del status cardiopulmonar preexistente. Segundo, los s&#237;ntomas y signos del TEP no son espec&#237;ficos de esta enfermedad. Entre los s&#237;ntomas que presentan los pacientes con TEP, ocurre disnea entre cerca de un 75% y un 85%, dolor a la inspiraci&#243;n entre aproximadamente un 65% y un 75% y tos en el 53% de ellos. </p>
      <p>En un estudio<sup>8</sup> que evalu&#243; trombosis cardiaca y embolia en 111 pacientes fallecidos por cardiopat&#237;a chag&#225;sica cr&#243;nica, del Instituto do Cora&#231;&#227;o, se observ&#243; embolia en el 60% de ellos, de los que el 65% era pulmonar. La embolia sist&#233;mica se hall&#243; en el 38% de los casos, y el &#225;rea renal estaba afectada en el 70% de los episodios. Se concluy&#243; que la incidencia de trombosis y embolia es alta en los enfermos con disfunci&#243;n mioc&#225;rdica severa, y que hay una relaci&#243;n entre ambas, aunque no absoluta. </p>
      <p>Este enfermo se someti&#243; a la tomograf&#237;a de t&#243;rax para que se elucidara los hallazgos de la radiograf&#237;a y se aclarara el diagn&#243;stico.</p>
      <p>La tomograf&#237;a de t&#243;rax evidenci&#243; linfonodos mediast&#237;nicos; micron&#243;dulos calcificados esparcidos por ambos pulmones; n&#243;dulo no calcificado de bordes que midian 1,6x1,4cm en el segmento basal medial del lobo inferior derecho; espesor de los septos interlobulares a la derecha; opacidad con atenuaci&#243;n de vidrio fosco predominando en las porciones promedios y base del pulm&#243;n derecho consolidaci&#243;n en la base del pulm&#243;n derecho. Ante este resultado, se hicieron las hip&#243;tesis que siguen a continuaci&#243;n: linfangitis pulmonar carcinomatosa, estasis o sarcoidosis. La hip&#243;tesis de tuberculosis se descart&#243; con culturas de esputo e investigaci&#243;n de BAAR negativas. </p>
      <p>La linfangitis carcinomatosa es m&#225;s com&#250;nmente originada de neoplasias primarias de mama, pulm&#243;n, est&#243;mago, colon, pr&#243;stata y p&#225;ncreas. Se debe llevar a cabo el diagn&#243;stico diferencial con otras enfermedades que tienen predilecci&#243;n por diseminaci&#243;n linf&#225;tica, como sarcoidosis, linfomas, leucemias, paracoccidioidomicosis, sarcoma de Kaposi, linfangiomatosis pulmonar difusa y linfangiectasia. El aspecto m&#225;s frecuentemente observado en la linfangitis carcinomatosa es el espesor de los septos interlobulares y de las vainas broncovasculares, pudiendo ser liso o nodular. Otros hallazgos comunes son n&#243;dulos distribuidos a lo largo de los linf&#225;ticos (superficie pleural, vainas broncovasculares, septos interlobulares y regi&#243;n centrolobular). Con frecuencia hay derrame pleural asociado. Una caracter&#237;stica importante es la preservaci&#243;n de la arquitectura pulmonar normal, sin evidencias de distorsi&#243;n parenquimatosa (fibrosis). En pacientes con disfunci&#243;n mioc&#225;rdica, principalmente de ventr&#237;culo derecho, la distinci&#243;n con cuadro de congesti&#243;n queda dificultada en los ex&#225;menes de im&#225;genes. Histol&#243;gicamente, los hallazgos b&#225;sicos en la linfangitis carcinomatosa son el espesor de los septos interlobulares y del intersticio peribroncovascular, por infiltraci&#243;n de c&#233;lulas neopl&#225;sicas dentro de los vasos linf&#225;ticos. Se debe tener en cuenta, sin embargo, que tambi&#233;n puede ocurrir espesor intersticial por fibrosis asociada a reacci&#243;n desmopl&#225;sica, por edema ocasionado por la obstrucci&#243;n linf&#225;tica o congesti&#243;n, o a&#250;n por una combinaci&#243;n de todos estos factores<sup>9</sup>.</p>
      <p>La sarcoidosis es una enfermedad sist&#233;mica de causa indeterminada, caracterizada por granulomas no caseosos. Afecta m&#225;s com&#250;nmente a mujeres que a varones, y tiene inicio en la tercera o cuarta d&#233;cada. Aunque pueda afectar cualquier &#243;rgano, esta enfermedad tiene su morbimortalidad relacionada principalmente al ataque pulmonar, presente desde el 80% hasta el 90% de los pacientes. El est&#225;ndar nodular es el m&#225;s frecuente en la sarcoidosis pulmonar. Los n&#243;dulos son generalmente peque&#241;os y presentan distribuci&#243;n perilinf&#225;tica, con envolvimiento de los haces peribroncovasculares, septos interlobulares, regiones centrolobulares subpleurales y a lo largo de las hendiduras. N&#243;dulos cavitados o de grandes dimensiones, por veces simulando neoplasias, se pueden encontrar en cerca de un 15% al 25% de los casos. Otros hallazgos tomogr&#225;ficos en la sarcoidosis son la opacidad en vidrio fosco, las opacidades parenquimatosas, el aprisionamiento a&#233;reo, las fibrosis y las bronquiectasias. El diagn&#243;stico necesita demostraci&#243;n histol&#243;gica de granulomas no caseosos en la bi&#243;psia<sup>10</sup>.</p>
      <p>La congesti&#243;n pulmonar cr&#243;nica por aumento de la presi&#243;n hidrost&#225;tica puede revelar alteraciones en la tomograf&#237;a del t&#243;rax, como bronquios de paredes engrosadas y aparente aumento del calibre de vasos pulmonares centrales y perif&#233;ricos. Debido al mantenimiento del aumento de la presi&#243;n intersticial hay el surgimiento de los septos interlobulares, los que est&#225;n engrosados por infiltraci&#243;n l&#237;quida. Otro aspecto encontrado en el edema intersticial es la presencia de opacidades en vidrio fosco<sup>11,12</sup>.</p>
      <p>Ante el expuesto, y con base en la descripci&#243;n de la tomograf&#237;a de t&#243;rax, ninguna de las tres hip&#243;tesis anteriores se puede desconsiderar, visto que ser&#225;n necesarios datos histol&#243;gicos.</p>
      <p>En la evoluci&#243;n, el paciente recibi&#243; nuevamente antibi&#243;ticos y dobutamina. El 07 de julio, present&#243; cuadro de congesti&#243;n pulmonar, que mejor&#243; con mediciones cl&#237;nicas, y el d&#237;a siguiente sufri&#243; parada cardiorrespiratoria (PCR) en actividad el&#233;ctrica sin pulso (AESP), sin &#233;xito, las maniobras de reanimaci&#243;n.</p>
      <p>Entre las hip&#243;tesis de PCR en AESP y de acuerdo con las consideraciones anteriores concluimos que la <italic>causa mortis</italic> fue tromboembolia pulmonar.</p>
      <p>Dra. Angela Cristina Matera Bolonhez</p>
      <p> y Dr. Murilo Capreti Silva</p>
      <p><bold>Hip&#243;tesis diagn&#243;stica principal:</bold> tromboembolismo pulmonar; miocardiopat&#237;a dilatada chag&#225;sica. </p>
      <p><bold>Otras hip&#243;tesis:</bold> linfangitis pulmonar carcinomatosa secundaria a la neoplasia pulmonar primaria; congesti&#243;n pulmonar cr&#243;nica; y menos probable sarcoidosis pulmonar. </p>
      <p>
        <bold>Necropsia</bold>
      </p>
      <p>En el examen morfol&#243;gico del coraz&#243;n se observ&#243; coraz&#243;n aumentado de volumen, globoso (<xref ref-type="fig" rid="fig06-body2">Figura 6A</xref>), con &#225;reas de engrosamiento peric&#225;rdico ("manchas l&#225;cteas"), y miocarditis cr&#243;nica focal diseminada (<xref ref-type="fig" rid="fig06-body2">Figura 6B</xref>), algunas de las caracter&#237;sticas cl&#225;sicas de la forma miocardiopat&#237;a chag&#225;sica; sin embargo, no hab&#237;a medici&#243;n de la punta del ventr&#237;culo izquierdo y no se detectaron nidos de <italic>Trypanosoma cruzi</italic> (como, adem&#225;s, frecuentemente no lo son).</p>
      <fig id="fig06-body2">
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf04-es.jpg"/></fig>
      <p>En el ri&#241;&#243;n y en los pulmones hab&#237;a tromboembolismo (<xref ref-type="fig" rid="fig07-body2">Figura 7</xref>), con infarto reciente, considerando que el compromiso de &#233;stos &#250;ltimos fue el factor final desencadenante de la muerte del paciente. No se hallaron fuentes de &#233;mbolos.</p>
      <fig id="fig07-body2">
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf05-es.jpg"/></fig>
      <p>Los pulmones presentaban tambi&#233;n adenocarcinoma con diseminaci&#243;n en patr&#243;n miliar para el propio &#243;rgano, bilateralmente (<xref ref-type="fig" rid="fig08-body2">Figura 8A</xref> y <xref ref-type="fig" rid="fig08-body2">B</xref>). No se puede descartar que esta enfermedad haya influenciado la formaci&#243;n de trombos, porque se vieron vasos con compromiso neopl&#225;sico en las regiones de edema e infarto. Se pone en contra esa posibilidad la existencia de co&#225;gulo en vaso renal, conllevando infarto, sin neoplasia. Sin embargo, incluso ah&#237; la trombosis puede ser una manifestaci&#243;n paraneopl&#225;sica. </p>
      <fig id="fig08-body2">
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf06-es.jpg"/></fig>
      <p>
        <bold>Dr. Paulo Sampaio Gutierrez</bold>
      </p>
      <p><bold>Diagn&#243;sticos principales:</bold> 1) Enfermedad de Chagas, forma cr&#243;nica cardiaca; 2) Adenocarcinoma del pulm&#243;n, con diseminaci&#243;n miliar. </p>
      <p><bold><italic>"Causa mortis"</italic>:</bold> tromboembolismo pulmonar. </p>
      <p>
        <bold>Dr. Paulo Sampaio Gutierrez</bold>
      </p>
      <p>
        <bold>Comentario</bold>
      </p>
      <p>El cuadro cl&#237;nico de este paciente, portador de enfermedad de Chagas, forma cr&#243;nica cardiaca, result&#243; complicado debido a la asociaci&#243;n al adenocarcinoma de pulm&#243;n.</p>
      <p>La asociaci&#243;n de enfermedad de Chagas con neoplasia es rara. Entre las 240 necropsias con esa enfermedad infecciosa en el Instituto do Cora&#231;&#227;o, los casos, adem&#225;s del presente, correspond&#237;an a un paciente con mesotelioma, dos mujeres con historia cl&#237;nica de tratamiento previo de c&#225;ncer de mama y un linfoma en paciente sometido con antelaci&#243;n a transplante cardiaco. De toda forma, esa poblaci&#243;n no es representativa. Es muy probable que la enfermedad de Chagas, notadamente en su forma indeterminada, aparezca m&#225;s como hallazgo secundario en portadores de neoplasias malignas que lo contrario, representado por nuestro material.</p>
      <p>Se describe la presencia de neoplasias en pacientes sometidos a transplantes. Levantamientos realizados en nuestro pa&#237;s evidenciaron que, entre los transplantados cardiacos, la incidencia de neoplasias se hall&#243; mayor en aquellos cuyo transplante fue motivado por la enfermedad de Chagas<sup>13</sup>. Sin embargo, no hubo relato de neoplasia pulmonar<sup>14</sup>. Los trabajos sobre la asociaci&#243;n entre enfermedad de Chagas y neoplasias son raros. Almeida et al relatan que la literatura acerca del asunto revela que este tema es controvertido, y que no se verific&#243; aumento o reducci&#243;n en la frecuencia de neoplasias malignas en chag&#225;sicos cr&#243;nicos. Indican todav&#237;a que la neoplasia maligna no interfiere en la evoluci&#243;n a corto plazo de la cardiopatia<sup>15</sup>. Hay relatos de la asociaci&#243;n de carcinoma de colon con megacolon chag&#225;sico<sup>16</sup>, aun as&#237; algunos autores consideran que &#233;ste &#250;ltimo sea quiz&#225; un factor de protecci&#243;n para el c&#225;ncer<sup>17</sup>. No obstante, en cuanto al megaes&#243;fago, parece haber determinada concordancia respecto de la relaci&#243;n entre las enfermedades, aunque la incidencia encontrada de c&#225;ncer en el megaes&#243;fago chag&#225;sico var&#237;a, con relatos de tasas del 3,9% y del 10%<sup>18</sup> , por ejemplo.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Clinicopathologic Session</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Case 4/2009: a 55-year-old male patient with Chagas cardiomyopathy who developed progressive worsening of dyspnea, chest pain and pulmonary interstitial infiltrate</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <bold>Case 4/2009 &#150; a 55-year-old male patient with Chagas cardiomyopathy who developed progressive worsening of dyspnea, chest pain and pulmonary interstitial infiltrate</bold>
      </p>
      <p>
        <bold>Angela Cristina Matera Bolonhez; Murilo Capreti da Silva; Rodrigo Caruso Chate; Paulo Sampaio Gutierrez</bold>
      </p>
      <p>Instituto do Cora&#231;&#227;o (InCor) HC-FMUSP, S&#227;o Paulo</p>
      <p><bold>Key words:</bold> Chagas Disease; Dyspnea; Bundle-Branch Block; Ventricular Dysfunction</p>
      <p>A 55-year-old man, a retired bricklayer, born in Itapetim (State of Pernambuco, Brazil), sought medical care due to shortness of breath (11/04/2005). </p>
      <p>Three years earlier, he had started to develop progressive worsening of dyspnea, which was initially triggered by severe exertion. One year earlier, dyspnea started to be triggered by moderate exertion and was associated with tachycardic palpitations. The patient sought medical care in a primary health care unit where he was prescribed medications, the names of which he could not recall. He improved after the use of these medications. He had been previously diagnosed with Chagas disease.</p>
      <p>The patient was receiving carvedilol 3.125 mg bid, digoxin 0.25 mg, spironolactone 25 mg, acetylsalicylic acid 100 mg, and hydrochlorothiazide 12.5 mg in combination with amiloride 1.25 mg daily. </p>
      <p>Physical examination revealed weight of 74.8 kg, height of 1.64 m, body mass index of 27.8 kg/m<sup>2</sup>, pulse of 78 beats per minute, and blood pressure of 110/80 mmHg. Lung examination was normal. Heart examination revealed normal heart sounds, regular rhythm, no extra sounds, clicks or murmurs. Abdominal examination was normal. There was no leg edema.</p>
      <p>Electrocardiogram (11/01/2005) showed sinus rhythm and low-amplitude R-waves in limb and precordial leads; intraventricular conduction abnormality; left ventricular; and atrial overload (<xref ref-type="fig" rid="fig01-body3">Figure 1</xref>). </p>
      <fig id="fig01-body3">
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf01-en.jpg"/></fig>
      <p>Chest radiography showed grade 3/4 cardiomegaly.</p>
      <p>A diagnosis of heart failure secondary to chagasic cardiomyopathy was made. </p>
      <p>Medication adjustment was made with discontinuation of acetylsalicylic acid and of the combination hydrochlorothiazide/amiloride, and increase in the carvedilol dose to 6.25 mg bid; enalapril was added at 10 mg bid. </p>
      <p>A test for detection of anti-<italic>Trypanosoma cruzi </italic>antibody was positive (11/3/2005).</p>
      <p>Radiocardiography (gated blood pool) (6/14/2006) with <sup>99m</sup>Technetium-labeled red blood cells showed bilateral abnormal rhythm of ventricular clearance of the tracer and bulging of the main pulmonary artery. The mean pulmonary transit time was longer than 20 seconds. The right atrium and ventricle were enlarged. There was marked diffuse right ventricular hypokinesia. The left ventricle was significantly enlarged and there was marked diffuse hypokinesia and dyskinesia in the left ventricular inferior apical region. Motion of the left ventricular inferior apical region was in phase opposition in relation to the other walls. The left ventricular and right ventricular ejection fractions were estimated at 13% and 24%, respectively.</p>
      <p>Laboratory tests (07/13/2006) revealed: hemoglobin 18.1 g/dL, hematocrit 54%, MCV 100 fl, MCHC 34 g/dL, 5.4 x 10<sup>6</sup> erythrocytes per mm<sup>3</sup>, 6.9 x 10<sup>3</sup> leukocytes per mm<sup>3</sup> (neutrophils 72%, eosinophils 2%, lymphocytes 18%, monocytes 8%), sodium 137 mEq/L, potassium 5.1 mEq/L, BUN 82 mg/dL, creatinin 1.1 mg/dL, aspartate aminotransferase 36 U/L, alanine aminotransferase 56 U/L, uric acid 7.3 mg/dL, albumin 3.7 g/dL, total bilirubin 1.36 mg/dL (direct 0.68 mg/dL, indirect 0.68 mg/dL), prothrombin time 19.3 sec (INR 1.45), 24-hour proteinuria 0.14g (normal up to 0.15). Stool examination for parasites (Hoffman, Rugai) was negative; carcinoembryonic antigen was 2.8 ng/mL (reference value up to 5.0 ng/mL).</p>
      <p>The patient underwent cardiac catheterization (8/3/2006) which showed moderate pulmonary hypertension (<xref ref-type="table" rid="tab01-body3">Table 1</xref>), however without any obstructive lesions in coronary arteries.</p>
      <table-wrap id="tab01-body3">
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gt01-en.jpg"/></table-wrap>
      <p>Pulmonary ventilation-perfusion scintigraphy (9/12/2006) was consistent with a low probability of pulmonary embolism. </p>
      <p>In 10/06/2006, the patient complained of tiredness on exertion and leg edema. The diuretic dose was increased with furosemide 80 mg daily in addition to the medication he was already receiving. </p>
      <p>In 11/03/2006, BUN was 81 mg/dL, creatinin 1.55 mg/dL, and serum potassium 4.9 mEq/L.</p>
      <p>In one of his outpatient visits (12/04/2006), he complained of shortness of breath, episodes of dizziness and presyncope 15 days earlier. He also complained of leg and abdominal edema. He was receiving hydralazine 25 mg bid, furosemide 40 mg bid, as well as spironolactone, carvedilol, enalapril and digoxin. He was advised to adjust his diet, activity and medication; the diuretic dose was reduced. </p>
      <p>Echocardiogram (01/03/2007) showed: aorta 32 mm, left atrium 52 mm, right ventricle 30 mm, interventricular septum 8 mm, left ventricular posterior wall 8 mm, left ventricular diastolic diameter 76 mm, left ventricular systolic diameter 66 mm, left ventricular ejection fraction (Teichholz) 27%. Doppler imaging study showed flow patterns consistent with a restrictive pattern, which reverted after Valsalva maneuver. The heart valves were considered normal. The pulmonary artery systolic pressure was estimated at 55 mmHg.</p>
      <p>The symptoms improved after the medication adjustment made in December (01/12/2007). </p>
      <p>Laboratory assessment in the follow-up showed: fasting plasma glucose 106 mg/dL (09/18/2007), B-type natriuretic peptide 1021 pg/mL (reference value: &lt;100 pg/mL), cholesterol 220 mg/dL, HDL-cholesterol 39 mg/dL, LDL-cholesterol 157 mg/dL, TSH 2.87 mIU/mL, free T<sub>4</sub> 1.7 ng/dL, blood glucose 106 mg/dL, glycosylated hemoglobin 6.1%, CA 19.9 2.6 U/mL (reference value up to 37 U/mL) (10/29/2007). </p>
      <p>Abdominal ultrasonography (05/12/2008) showed atheromatous aorta and hyperechoic nodular lesions in the liver, considered as consistent with hemangiomas. </p>
      <p>In 06/03/2008, the patient developed cough with yellow sputum, in addition to dyspnea. He sought medical care in a Primary Health Care Unit and was prescribed levofloxacin 500 mg once a day. There was clinical improvement.</p>
      <p>He later sought medical care again (07/03/2008) due to persistent chest pain for two days, which worsened with deep breath or cough and radiated to the back; he also presented bloody sputum.</p>
      <p>He was receiving carvedilol 50 mg, enalapril 40 mg, digoxin 0.125 mg, furosemide 40 mg, hydrochlorothiazide 25 mg, spironolactone 25 mg, and omeprazol daily.</p>
      <p>Physical examination revealed pulse of 80 beats per minute and blood pressure of 80/40 mmHg. The rest of the physical examination was negative for other diagnostic clues. </p>
      <p>Electrocardiogram performed in 07/03/2008 did not show any significant change in relation to the previous test. </p>
      <p>Chest radiography (07/03/2008) showed an image suggestive of diffuse reticular-alveolar infiltrate in the lungs. CT scan of the chest (07/03/2008) showed mediastinal vascular structures of normal diameter and regular contours; cardiomegaly; mediastinal lymph nodes smaller than 10 mm; sparse calcified micronodules in both lungs; non-calcified nodule with spiculated borders measuring 1.6 x 1.4cm in the medial-basal segment of the RLL; diffuse micronodules with centrolobular distribution in both lungs; thickened interlobular septae in the right lung; opacity with ground-glass attenuation predominantly in mid and basal portions of the right lung; and consolidation in the right lung base. </p>
      <p>The diagnoses of lymphangitis, stasis or sarcoidosis were postulated.</p>
      <p>Sputum culture for mycobacteria and acid-fast bacilli test (07/04/2009) were both negative.</p>
      <p>The patient received intravenous clarithromycin 500 mg every 12 hours and intravenous ceftriaxone 1g every 12 hours, in addition to the cardiovascular medication he already used. Dobutamine was also administered. </p>
      <p>In 07/07/2008, he presented a clinical picture described as acute pulmonary edema, which improved with the use of diuretics, non-invasive ventilation and vasodilators.</p>
      <p>The next day (07/08/2009), the patient suffered cardiac arrest with pulseless electrical activity which failed to respond to resuscitation efforts.</p>
      <p>
        <bold>Comments &#150; InCor chest radiologist</bold>
      </p>
      <p>In the CT scan of the chest performed without intravenous iodine contrast medium, a non-calcified pulmonary nodule with lobulated contours was identified in the right lower lobe, whose tomographic aspect was suggestive of primary neoplasia (<xref ref-type="fig" rid="fig02-body3">Figure 2</xref>). In the right lung, there was associated peribronchovascular and septal interstitial thickening, sometimes with smooth aspect and with a micronodular pattern in some regions, which led to the possibility of carcinomatous lymphangitis (<xref ref-type="fig" rid="fig02-body3">Figures 2 to 4</xref>). Worthy of note were also multiple small non-calcified nodules disseminated in all lung fields, which, in this clinical context, are consistent with secondary lesions (<xref ref-type="fig" rid="fig02-body3">Figures 2 to 4</xref>). The tomographic views also revealed sparse foci of pulmonary consolidation with pleural base bilaterally; they were surrounded by ground-glass opacities and predominated in the basal segments of the right lower lobe (<xref ref-type="fig" rid="fig05-body3">Figure 5</xref>). They were consistent with infarct areas and pulmonary hemorrhage in the clinical setting of acute thromboembolism. <bold>(Dr. Rodrigo Caruso Chate)</bold> </p>
      <fig id="fig02-body3">
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf02-en.jpg"/></fig>
      <p>
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-e01-en.jpg"/></p>
      <p>
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-e02-en.jpg"/></p>
      <fig id="fig05-body3">
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf03-en.jpg"/></fig>
      <p>
        <bold>Clinical aspects</bold>
      </p>
      <p>The patient is a 55-year-old male who, in November 2005, sought medical care due to dyspnea which had worsened progressively for three years and was associated with tachycardic palpitations; he had serologic tests positive for Chagas disease. Physical examination was normal; electrocardiogram (ECG) showed left bundle branch block and low-amplitude R-waves; chest radiography showed enlarged cardiac silhouette (grade 3/4 cardiomegaly), consistent with heart failure whose probable cause was Chagas disease in its chronic dilated cardiomyopathy form. He used low doses of carvedilol in addition to digoxin, acetylsalicylic acid, spironolactone, hydrochlorothiazide, and amiloride. Medication adjustment was made with the introduction of angiotensin-converting enzyme inhibitor (enalapril) and follow-up was started.</p>
      <p>Some considerations regarding the etiology of heart failure can be made. Chagas disease in its chronic form is characterized by diversity. There are asymptomatic patients in the indeterminate form, asymptomatic patients with electrocardiographic abnormalities, and symptomatic patients with varying degrees of ventricular dysfunction. There are severe atrioventricular and intraventricular conduction disturbances, those with thromboembolic phenomena, and with varying degrees of ventricular arrhythmias<sup>1-4</sup>. Conduction abnormalities are, undoubtedly, the most common alterations. The classic abnormality described is complete right bundle branch block, whether or not associated with left bundle branch antero-superior block<sup>5-6</sup>. In the clinical practice, a history suggestive of the disease and the finding of these alterations strongly suggest Chagas disease in our midst. Left bundle branch block (LBBB) frequently observed in dilated cardiomyopathy is present in Chagas heart disease, although with a very low incidence. Studies demonstrated the finding of LBBB in these patients accompanied or not by dysfunction in between zero and 3.1% of the patients<sup>2,5</sup>.</p>
      <p>Progression time of Chagas heart disease is longer than that of all other etiologies, with durations commonly longer than twenty years, so that the heart can optimize all compensatory mechanisms. Thus, the patients remain with no or few symptoms for years or even decades. When the patient decompensates, it is because the myocardial damage has exceeded all compensatory mechanisms, thus making the disease more severe<sup>1</sup>.</p>
      <p>The prognosis of the chronic form of Chagas cardiomyopathy is related to the degree of ventricular dysfunction as assessed by left ventricular ejection fraction (EF); the lower the EF, the worse the prognosis (like in other cardiomyopathies). There is also a correlation with the functional class and oxygen consumption<sup>1-4</sup>. Additionally, the disease is more aggressive in men, and the reason for this remains unknown<sup>7</sup>.</p>
      <p>From the first visit, the analysis of this patient's ECG and chest radiography showed severe myocardial impairment due to Chagas disease, as evidenced by the presence of interventricular conduction disturbance, low-amplitude R-waves, and significantly enlarged cardiac silhouette. These findings, together with the patient's symptoms, lead to the presumption of severe dilated cardiomyopathy. </p>
      <p>Radiocardiography performed in the follow-up showed severe left ventricular hypokinesia (EF = 13%), with dyskinesia of the inferior-apical region, as well as right ventricular hypokinesia (EF = 24%), with bulging of the main pulmonary artery, thus confirming severe systolic dysfunction with secondary pulmonary hypertension (PH). Among the laboratory tests, the high hemoglobin level (18 g/dL) is worthy of attention, and may be justified by pulmonary hypertension; also, a mildly decreased renal function was possibly due to the use of diuretics or to the low cardiac output.</p>
      <p>The patient underwent cardiac catheterization, whose pressure measurements showed moderated pulmonary hypertension with no obstructive coronary lesions, thus ruling out coronary artery disease. PH was partially reverted with nitroprusside and oxygen mask. Pulmonary vascular resistance dropped from 6.3 U Wood to 2.2 U Wood. To further investigate PH, pulmonary perfusion scintigraphy was performed, showing a low probability of pulmonary embolism. </p>
      <p>As to thromboembolic complications, especially pulmonary, these can be the first manifestation of the disease. Regional deficits may determine thrombosis, even with preserved global function. Patients at a higher risk are those with severe myocardial dysfunction, atrial fibrillation, LV apical lesion, presence of intracavitary thrombi, and previous embolism<sup>8</sup>.</p>
      <p>During the follow-up, 11 months after the first visit, the patient presented worsening of the functional class, and the diuretic dose was increased. His renal function slightly worsened. Two months later, in another visit, he presented symptoms of low cardiac output, with dizziness and presyncope.</p>
      <p>In this phase of the disease, we applied the score elaborated by Rassi et al<sup>3</sup> for the assessment of the risk of death in patients with Chagas disease, which takes into consideration functional classes III and IV (NYHA) (5 points); evidence of cardiomegaly on chest radiography (5 points); LV systolic dysfunction on echocardiography (3 points); non-sustained ventricular tachycardia on Holter monitoring (3 points); low-voltage QRS on ECG (2 points); and male gender (2 points). This patient's score was 17, which classified him in the high-risk group, with 63% mortality in five years and 84% in 10 years<sup>2</sup>. Therefore, this patient was progressing to stage-D heart failure, and the possibility of cardiac transplantation could have been considered.</p>
      <p>Cardiac transplantation is indicated in symptomatic patients in functional class III or IV (NHYA) during drug therapy properly optimized, with life expectancy of less than one year, and no possibility of other medical or conventional surgical treatment. </p>
      <p>Pulmonary hypertension is a factor that precludes cardiac transplantation and represents the main cause of RV dysfunction of the graft in the immediate postoperative period. Pulmonary vascular resistance higher than 2.5 U Woods has been pointed out as an important risk factor, considering that mortality progressively increases above these levels. Thus, in the present case, there was no contraindication for cardiac transplantation. </p>
      <p>In January 2007, the patient underwent echocardiography, which showed significant left atrial enlargement (52 mm); LV diastolic and systolic diameters of 76 mm and 66 mm, respectively; EF of 27%; and pulmonary artery systolic pressure of 55 mmHg.</p>
      <p>In the third follow-up visit, after diuretic reduction, there was improvement of the symptoms; with the purpose of a preoperative assessment for a possible transplantation, the patient underwent a series of tests. One of the results, a BNP level of 1021 pg/mL, suggested advanced decompensated heart failure despite the optimized therapy.</p>
      <p>Abdominal ultrasonography showed atheromatous aorta and hyperechoic nodular lesions consistent with hemangiomas.</p>
      <p>In June 2008, the patient developed pneumonia and was treated with levofloxacin, with subsequent improvement. One month later, he developed persistent chest pain for two days, which worsened with deep breath and cough and radiated to the back; he also presented hemoptysis and hypotension. Electrocardiogram did not show differences in relation to the previous test; chest radiography showed an image suggestive of diffuse reticular-alveolar infiltrate in both lungs.</p>
      <p>At that moment, the diagnostic hypotheses were alveolar hemorrhage secondary to pulmonary hypertension, complicated bronchopneumonia, tuberculosis and pulmonary thromboembolism (PTE). The latter should always be included in the differential diagnosis of this type of patient seen in the emergency room.</p>
      <p>The clinical diagnosis of PTE is particularly difficult for two reasons. First, the clinical findings depend both on the size of the embolus and on the preexisting cardiopulmonary status. Second, the signs and symptoms of PTE are not specific of this disease. Among the symptoms, dyspnea occurs in approximately 75% to 85%, pain with breathing in approximately 65% to 75%, and cough in 53% of the patients with PTE.</p>
      <p>In a study<sup>8</sup> assessing cardiac thrombosis and embolism in 111 patients who died of chronic Chagas heart disease in the <italic>Instituto do Cora&#231;&#227;o, </italic>embolism was observed in 60% of them; of these, 65% had pulmonary embolism. Systemic embolism was found in 38% of the cases, and the renal region was affected in 70% of the episodes. We can conclude that the incidence of thrombosis and embolism is high among patients with severe myocardial dysfunction, and there is a relationship between both conditions, although not absolute. </p>
      <p>This patient underwent CT scan of the chest to elucidate the radiographic findings and clarify the diagnosis.</p>
      <p>CT scan of the chest showed mediastinal lymph nodes; sparse calcified micronodules in both lungs; non-calcified nodule with spiculated borders measuring 1.6 x 1.4 cm in the medial-basal segment of the right lower lobe; interlobular septal thickening in the right lung; opacity with ground-glass attenuation, predominating in the mid and basal portions of the right lung; and consolidation in the right lung base. </p>
      <p>In view of these findings, the following hypotheses were made: carcinomatous pulmonary lymphangitis, stasis or sarcoidosis. The hypothesis of tuberculosis was ruled out because of negative sputum cultures and acid-fast bacilli test. </p>
      <p>Carcinomatous lymphangitis more commonly originates from primary breast, lung, stomach, colon, prostate, and pancreas neoplasms. Differential diagnosis should be made with other diseases which preferably disseminate via the lymphatic vessels, such as sarcoidosis, lymphomas, leukemias, paracoccidioidomycosis, Kaposi's sarcoma, diffuse pulmonary lymphangiomatosis, and lymphangiectasia. The aspect most frequently observed in carcinomatous lymphangitis is interlobular septa and bronchovascular sheath thickening, and this can be smooth or nodular. Other common findings are nodules distributed along the lymphatic vessels (pleural surface, bronchovascular sheaths, interlobular septa and centrolobular region). Pleural effusion is a frequent association. An important characteristic is the preservation of the normal pulmonary architecture, with no signs of parenchymal distortion (fibrosis). In patients with myocardial dysfunction, particularly right ventricular dysfunction, the differential diagnosis with congestion is difficult to be made by means of imaging studies. The basic histological findings in carcinomatous lymphangitis are interlobular septal and peribroncovascular interstitial thickening due to neoplastic cell infiltration inside the lymphatic vessels. However, it should be considered that interstitial thickening can also result from fibrosis associated with desmoplastic reaction, from edema caused by lymphatic obstruction or congestion, or still from a combination of all these factors<sup>9</sup>.</p>
      <p>Sarcoidosis is a systemic disease of unknown cause, characterized by noncaseating granulomas. It affects women more frequently than men, and manifests in the third or fourth decades. Although it can affect any organ, and its morbidity and mortality are mainly related to the pulmonary involvement, which is present in 80% to 90% of the patients. The nodular pattern is the most frequently seen in pulmonary sarcoidosis. The nodules are usually small and are distributed along the lymphatic vessels; they are located in the peribronchovascular bundles, interlobular septa, subpleural centrolobular regions, and along the fissures. Cavitary or large nodules, sometimes suggesting neoplasia, may be found in 15% to 25% of the cases. Other tomographic findings in sarcoidosis are ground-glass opacities, parenchymatous opacities, air trapping, fibrosis and bronchiectasias. The diagnosis requires histological demonstration of noncaseating granulomas on biopsy<sup>10</sup>.</p>
      <p>Chronic pulmonary congestion due to increased hydrostatic pressure may lead to alterations in the CT scan of the chest, like bronchi with thickened walls and apparent increase in the diameter of central and peripheral pulmonary vessels. With the persistence of increased interstitial pressure, the image of the interlobular septa &#150; which are thickened due to fluid infiltration, becomes noticeable. Another aspect found in interstitial edema is the presence of ground-glass opacities<sup>11,12</sup>.</p>
      <p>In view of the exposed, and based on the description of the CT scan of the chest, none of the three hypotheses mentioned was ruled out, since they require histological data. </p>
      <p>During the follow-up, the patient received antibiotics and dobutamine again. On July 7th, the patient developed pulmonary congestion, which improved with clinical measures. The next day, he suffered a cardiopulmonary arrest (CPA) in pulseless electrical activity (PEA); resuscitation efforts were unsuccessful.</p>
      <p>Considering the hypothesis for CPA in PEA, and according to the considerations previously made, we conclude that the cause of death was pulmonary thromboembolism. <bold>(Dra. Angela Cristina Matera Bolonhez and Dr. Murilo Capreti Silva)</bold> </p>
      <p><bold>Main diagnostic hypothesis: </bold>Pulmonary Thromboembolism; Dilated Chagas Cardiomyopathy.</p>
      <p><bold>Other hypotheses: </bold>Carcinomatous pulmonary lymphangitis secondary to primary lung neoplasia; chronic pulmonary congestion; and, less likely, pulmonary sarcoidosis.</p>
      <p>
        <bold>Necropsy</bold>
      </p>
      <p>The morphological examination of the heart revealed enlarged globoid heart (<xref ref-type="fig" rid="fig06-body3">Figure 6A</xref>), with areas of pericardial thickening ("milky spots"), and disseminated focal chronic myocarditis (<xref ref-type="fig" rid="fig06-body3">Figure 6B</xref>), which are some of the classic characteristics of Chagas cardiomyopathy. However, tapering of the left ventricular apex was not observed. Likewise, <italic>Trypanosoma cruzi </italic>nests were not detected (as usually occurs, in fact).</p>
      <fig id="fig06-body3">
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf04-en.jpg"/></fig>
      <p>Thromboembolism was observed in the kidney and lungs (<xref ref-type="fig" rid="fig07-body3">Figure 7</xref>), with recent infarction. The involvement of these two organs was the final factor triggering the death of the patient. The source of the emboli was not found.</p>
      <fig id="fig07-body3">
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf05-en.jpg"/></fig>
      <p>The lungs also presented adenocarcinoma with bilateral miliary dissemination to the organ itself (<xref ref-type="fig" rid="fig08-body3">Figure 8A</xref> and <xref ref-type="fig" rid="fig08-body3">B</xref>). It can not be ruled out that this disease had influenced thrombus formation, because vessels with neoplastic involvement were observed in the regions of edema and infarction. The existence of a clot in a renal vessel leading to infarction, without neoplasia, speaks against this possibility; however, even in this location, thrombosis can be a paraneoplastic manifestation. <bold>(Dr. Paulo Sampaio Gutierrez)</bold></p>
      <fig id="fig08-body3">
        <graphic xlink:href="1678-4170-abc-93-03-0316-00018-gf06-en.jpg"/></fig>
      <p><bold>Main diagnoses: </bold>1) Chagas disease, chronic cardiac form; 2) Pulmonary adenocarcinoma with miliary dissemination.</p>
      <p><bold>Cause of death: </bold>pulmonary thromboembolism <bold>(Dr. Paulo Sampaio Gutierrez)</bold></p>
      <p>
        <bold>Comment</bold>
      </p>
      <p>The clinical picture of this patient with Chagas disease, chronic cardiac form, was complicated by the association with pulmonary adenocarcinoma.</p>
      <p>The association of Chagas disease with neoplasia is uncommon. Among the 240 autopsies with this infectious disease performed at the <italic>Instituto do Cora&#231;&#227;o</italic>, other cases of this association included one male patient with mesothelioma, two women with clinical history of previous treatment of breast cancer, and one patient with lymphoma who had previously undergone cardiac transplantation. Anyway, this population is not representative. It is very likely that Chagas disease, especially in its indeterminate form, is more usually a secondary finding in patients with malignant neoplasias than otherwise, as represented by our sample.</p>
      <p>Development of neoplasms is described in patients undergoing transplantation. Surveys conducted in Brazil showed that among heart transplanted patients, the incidents of neoplasias was higher in those whose transplantation was motivated by Chagas disease<sup>13</sup>; however, there were no reports of pulmonary neoplasias<sup>14</sup>. Studies on the association between Chagas disease and neoplasias are scarce. Almeida et al reported that the literature on the theme shows that this is a controversial issue, and that no increase or reduction in the frequency of malignant neoplasias was verified among patients with chronic Chagas disease. They also verified that malignant neoplasias do not interfere in the short-term course of the heart disease<sup>15</sup>. There are reports on the association of colon carcinoma with chagasic megacolon<sup>16</sup>; nonetheless, some authors consider that the latter is perhaps a protective factor against cancer<sup>17</sup>. As regards megaesophagus, there seems to be a certain agreement on the relationship between the diseases, even though the incidence found for cancer in chagasic megaesophagus is variable, with rates from 3.9% to 10% being reported<sup>18</sup>.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
